

Reduced sensitivity of SARS-CoV-2 variant Delta to ant

Nature

596, 276-280

DOI: [10.1038/s41586-021-03777-9](https://doi.org/10.1038/s41586-021-03777-9)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. SSRN Electronic Journal, 0, , .	0.4	3
4	The Efficacy and Safety of Bamlanivimab Treatment Against COVID-19: A Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
5	Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative caseâ€“control real-world study. Emerging Microbes and Infections, 2021, 10, 1751-1759.	3.0	206
7	Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune Escape. SSRN Electronic Journal, 0, , .	0.4	0
18	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host and Microbe, 2021, 29, 1063-1075.	5.1	99
20	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian Journal of Infectious Diseases, 2021, 25, 101606.	0.3	94
24	Not All Monoclonal Antibodies for Coronavirus Disease 2019 Are Created Equal. Journal of Infectious Diseases, 2021, 224, 1275-1277.	1.9	2
28	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
29	Graphene, Carbon Nanotube and Plasmonic Nanosensors for Detection of Viral Pathogens: Opportunities for Rapid Testing in Pandemics like COVID-19. Frontiers in Nanotechnology, 2021, 3, .	2.4	17
30	Educating society about the unseen, but not unknown, risk factors for severe COVID-19: a step towards overcoming vaccine hesitancy through a more informed public. Journal of Global Health Reports, 0, 5, .	1.0	0
35	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annual Review of Medicine, 2022, 73, 1-16.	5.0	91
37	Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Infectious Diseases and Therapy, 2021, 10, 2479-2488.	1.8	69
39	Molecular Level Dissection of Critical Spike Mutations in SARSâ€“CoVâ€“2 Variants of Concern (VOCs): A Simplified Review. ChemistrySelect, 2021, 6, 7981-7998.	0.7	18
41	Covid-19: How effective are vaccines against the delta variant?. BMJ, The, 2021, 374, n1960.	3.0	33
44	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cellular and Molecular Immunology, 2021, 18, 2455-2456.	4.8	35
48	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses, 2021, 13, 1693.	1.5	69
49	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554.	1.5	8
50	Evidence of SARS-CoV-2 Virus in the Middle Ear of Deceased COVID-19 Patients. Diagnostics, 2021, 11, 1535.	1.3	14

#	ARTICLE	IF	CITATIONS
51	Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 224, 1345-1356.	1.9	22
55	Adaptive staffing can mitigate essential worker disease and absenteeism in an emerging epidemic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
56	Severe Acute Respiratory Syndrome Coronavirus 2 Variant Delta Infects All 6 Siblings but Spares Comirnaty (BNT162b2, BioNTech/Pfizer)-Vaccinated Parents. <i>Journal of Infectious Diseases</i> , 2021, 224, 1984-1986.	1.9	6
59	Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics. <i>Indian Journal of Medical Microbiology</i> , 2021, 39, 417-422.	0.3	5
60	Evolutionary trajectory of SARS-CoV-2 and emerging variants. <i>Virology Journal</i> , 2021, 18, 166.	1.4	105
63	Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein. <i>Infectious Diseases of Poverty</i> , 2021, 10, 112.	1.5	8
64	Rapid Global Spread of the SARS-CoV-2 Delta (B.1.617.2) Variant: Spatiotemporal Variation and Public Health Impact. <i>Zoonoses</i> , 2021, 1, .	0.5	18
66	Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 2107-2119.	1.7	0
75	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. <i>Viruses</i> , 2021, 13, 1595.	1.5	23
77	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
78	Hybrid immunity: the immune response of COVID-19 survivors to vaccination. <i>Revista Bionatura</i> , 2021, 3, 1890-1892.	0.1	0
81	To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1211-1220.	2.0	85
82	Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19. <i>Pathogens</i> , 2021, 10, 1218.	1.2	4
83	Lectin from <i>Triticum vulgare</i> (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10205.	1.8	17
84	SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated. <i>Frontiers in Microbiology</i> , 2021, 12, 749634.	1.5	3
87	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
88	Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. <i>PLoS Computational Biology</i> , 2021, 17, e1009380.	1.5	13
90	Re: Oral antiseptics against coronavirus: in-vitro and clinical evidence. <i>Journal of Hospital Infection</i> , 2021, 118, 108-109.	1.4	4

#	ARTICLE	IF	CITATIONS
91	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
92	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. <i>Science Immunology</i> , 2021, 6, eabl4509.	5.6	141
93	A Novel Real-Time RT-PCR-Based Methodology for the Preliminary Typing of SARS-CoV-2 Variants, Employing Non-Extendable LNA Oligonucleotides and Three Signature Mutations at the Spike Protein Receptor-Binding Domain. <i>Life</i> , 2021, 11, 1015.	1.1	5
94	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. <i>Vaccines</i> , 2021, 9, 999.	2.1	23
95	A SARS-CoV-2 Neutralization Assay using Single Molecule Arrays. <i>Angewandte Chemie</i> , 0, , .	1.6	5
98	A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. <i>Expert Review of Vaccines</i> , 2021, 20, 1311-1325.	2.0	7
99	Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection. <i>Immunobiology</i> , 2021, 226, 152130.	0.8	10
100	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
102	Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 743325.	1.2	10
103	High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2021, 8, 735853.	1.2	7
105	SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters. <i>Viruses</i> , 2021, 13, 1773.	1.5	43
107	Organ transplant patients, COVID-19, and neutralizing monoclonal antibodies: The glass is half full. <i>Transplant Infectious Disease</i> , 2021, 23, e13724.	0.7	3
109	Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells. <i>Cells</i> , 2021, 10, 2355.	1.8	13
112	The "Delta Plus" COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 109-112.	0.7	43
114	Ginkgolic Acid Inhibits Coronavirus Strain 229E Infection of Human Epithelial Lung Cells. <i>Pharmaceuticals</i> , 2021, 14, 980.	1.7	4
117	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	15.2	178
118	Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab468.	0.4	10
119	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 1017.	2.1	10

#	ARTICLE	IF	CITATIONS
121	Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India. <i>Journal of Medical Virology</i> , 2022, 94, 407-412.	2.5	24
123	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	2.2	62
125	T cell-oriented strategies for controlling the COVID-19 pandemic. <i>Nature Reviews Immunology</i> , 2021, 21, 687-688.	10.6	54
126	Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection. <i>Research, Society and Development</i> , 2021, 10, e264101220410.	0.0	0
131	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
132	Why Does the SARS-CoV-2 Delta VOC Spread So Rapidly? Universal Conditions for the Rapid Spread of Respiratory Viruses, Minimum Viral Loads for Viral Aerosol Generation, Effects of Vaccination on Viral Aerosol Generation, and Viral Aerosol Clouds. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9804.	1.2	19
133	Finding the Middle Ground with the Clinical Laboratory's Role in SARS-CoV-2 Genomic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0181621.	1.8	1
137	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
139	The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. <i>Environmental Chemistry Letters</i> , 2022, 20, 1539-1544.	8.3	6
141	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
142	Antibody titers and protection against a SARS-CoV-2 infection. <i>Journal of Infection</i> , 2022, 84, 248-288.	1.7	94
144	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
145	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
150	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 374, n2231.	3.0	59
151	Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e224-e233.	2.9	10
152	COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF- κ B Pathway. <i>Viruses</i> , 2021, 13, 1887.	1.5	12
154	SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 349.	7.1	52
155	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. <i>European Journal of Immunology</i> , 2021, 51, 3202-3213.	1.6	76

#	ARTICLE	IF	CITATIONS
156	Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?. Expert Opinion on Biological Therapy, 2021, 21, 1359-1362.	1.4	4
158	Viral 3CLpro as a Target for Antiviral Intervention Using Milk-Derived Bioactive Peptides. International Journal of Peptide Research and Therapeutics, 2021, 27, 2703-2716.	0.9	10
159	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	6.6	107
160	SAR-CoV-2 infection, emerging new variants and the role of activation induced cytidine deaminase (AID) in lasting immunity. Saudi Pharmaceutical Journal, 2021, 29, 1181-1184.	1.2	6
161	The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19. Fungal Biology Reviews, 2021, 38, 67-91.	1.9	22
165	Impact of the Delta variant on vaccine efficacy and response strategies. Expert Review of Vaccines, 2021, 20, 1201-1209.	2.0	177
166	Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. The Lancet Healthy Longevity, 2021, 2, e685-e687.	2.0	27
167	A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays. Angewandte Chemie - International Edition, 2021, 60, 25966-25972.	7.2	21
168	ACE2-cytomimetic particles restrict SARS-Cov-2 spike protein binding to cellular targets. Biotechnology Reports (Amsterdam, Netherlands), 2021, 32, e00681.	2.1	4
170	Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Biochemical and Biophysical Research Communications, 2021, 574, 14-19.	1.0	70
171	Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021. Virus Research, 2021, 304, 198532.	1.1	15
172	Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. European Journal of Cancer, 2021, 156, 119-121.	1.3	7
173	SARS-CoV-2 Delta variant infects ACE2 ^{low} primary human bronchial epithelial cells more efficiently than other variants. Journal of Medical Virology, 2022, 94, 821-822.	2.5	4
174	Using Lung Base Covid-19 Findings To Predict Future Disease Trends and New Variant Outbreaks: Study Of First New York City (NYC) Outbreak.. Academic Radiology, 2021, 28, 1645-1653.	1.3	1
175	Is It Ethical to Mandate SARS-CoV-2 Vaccinations among Incarcerated Persons?. American Journal of Bioethics, 2022, 22, 8-10.	0.5	2
176	COVID-19 challenges and its therapeutics. Biomedicine and Pharmacotherapy, 2021, 142, 112015.	2.5	59
177	Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. Journal of Controlled Release, 2021, 338, 813-836.	4.8	30
178	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. Journal of Biological Chemistry, 2021, 297, 101151.	1.6	42

#	ARTICLE	IF	CITATIONS
179	Immunological response after mild COVID-19: How long will it last?. <i>EBioMedicine</i> , 2021, 72, 103597.	2.7	1
180	The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. <i>Journal of Molecular Biology</i> , 2022, 434, 167280.	2.0	92
181	The inÂvitro and inÂvivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 578, 91-96.	1.0	39
182	COVID-19 challenges: From SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms. <i>Biochemical Engineering Journal</i> , 2021, 176, 108200.	1.8	17
183	Identification of Broad Anti-Coronavirus Chemical Agents for Repurposing Against SARS-CoV-2 and Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
184	Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India. <i>SSRN Electronic Journal</i> , 0, , .	0.4	9
185	Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. <i>Zoological Research</i> , 2021, 42, 789-791.	0.9	28
186	N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5556-5567.	1.9	39
187	COVID-19 Acceleration and Vaccine Status in France - Summer 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
188	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	0.9	183
189	Are the COVID-19's vaccines efficient on the most dangerous variant of SARS-CoV-2?. <i>Clinical and Experimental Vaccine Research</i> , 2021, 10, 301.	1.1	0
190	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
191	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	9
192	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. <i>Vaccines</i> , 2021, 9, 1106.	2.1	5
193	Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100065.	1.7	7
194	Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19â€”a prospective multicenter cohort study. <i>BMC Medicine</i> , 2021, 19, 270.	2.3	22
195	mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€”Specific T Cells Persist at 6 Months and Recognize the Delta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e898-e901.	2.9	25
197	Analysis of SARS-CoV-2 Genomes from West Java, Indonesia. <i>Viruses</i> , 2021, 13, 2097.	1.5	15

#	ARTICLE	IF	CITATIONS
198	The challenges of COVID-19 Delta variant: Prevention and vaccine development. <i>MedComm</i> , 2021, 2, 846-854.	3.1	37
199	SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	2
200	New Evidence on the Evolution of the COVID-19 Pandemic: Literature Review. <i>Pediatrica</i> , 2021, 18, 314-319.	0.1	3
201	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
202	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. <i>MBio</i> , 2021, 12, e0247321.	1.8	35
203	T cell immunity to SARS-CoV-2. <i>Seminars in Immunology</i> , 2021, 55, 101505.	2.7	55
204	SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. <i>EMBO Journal</i> , 2021, 40, e108944.	3.5	139
205	Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2560-2562.	4.8	11
206	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
207	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
208	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. <i>Cell Reports</i> , 2021, 37, 109869.	2.9	59
209	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
210	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
211	Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 1039.	1.3	2
214	COVID-19 convalescent plasma. <i>Blood</i> , 2022, 140, 196-207.	0.6	31
216	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
217	Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	21
218	Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients. <i>Viruses</i> , 2021, 13, 2011.	1.5	9

#	ARTICLE	IF	CITATIONS
219	Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. <i>Science</i> , 2021, 374, 995-999.	6.0	230
222	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	2.0	12
223	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
224	Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 369.	7.1	16
225	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
226	Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. <i>Frontiers in Microbiology</i> , 2021, 12, 750725.	1.5	11
227	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	2.1	3
229	Indirect-Acting Pan-Antivirals vs. Respiratory Viruses: A Fresh Perspective on Computational Multi-Target Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 2687-2693.	1.0	5
230	Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy. <i>Emerging Microbes and Infections</i> , 2021, 10, 2010-2015.	3.0	17
232	Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19. <i>Microorganisms</i> , 2021, 9, 2167.	1.6	36
234	SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10836.	1.8	25
236	In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants. <i>Pharmaceuticals</i> , 2021, 14, 1055.	1.7	13
237	No one is safe until we are all safe. <i>Science Translational Medicine</i> , 2021, 13, eabl9900.	5.8	5
238	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
239	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	3.1	21
240	Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2557-2559.	4.8	41
242	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COVS immunogenicity in a variant-dependent manner. <i>Cell Host and Microbe</i> , 2021, 29, 1611-1619.e5.	5.1	106
244	Resistance of SARS-CoV-2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. <i>Transfusion</i> , 2021, , .	0.8	8

#	ARTICLE	IF	CITATIONS
246	Random Forest to Predict Eucalyptus as a Potential Herb in Preventing Covid19. , 2021, , .		1
247	Clinical Presentation of a COVID-19 Delta Variant Patient: Case Report and Literature Review. Cureus, 2021, 13, e18603.	0.2	5
249	A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. MBio, 2021, 12, e0254221.	1.8	18
250	Battle against the pandemic: Emergence of SARS-CoV2 variants and global challenge. Travel Medicine and Infectious Disease, 2021, 44, 102173.	1.5	3
251	Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerging Infectious Diseases, 2021, 27, 3178-3180.	2.0	13
252	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. Biomedicine and Pharmacotherapy, 2021, 144, 112276.	2.5	9
253	Immune interventions in COVID-19: a matter of time?. Mucosal Immunology, 2022, 15, 198-210.	2.7	14
254	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	6.0	246
255	Burnout Among Healthcare Workers in the COVID 19 Era: A Review of the Existing Literature. Frontiers in Public Health, 2021, 9, 750529.	1.3	144
257	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 2021, 13, 2177.	1.5	21
258	Electrophysiology and Interventional Cardiology Procedure Volumes During the COVID-19 Pandemic. Cardiac Electrophysiology Clinics, 2021, 14, 105-110.	0.7	3
259	Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. Advanced Science, 2022, 9, e2102181.	5.6	14
261	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	7.0	40
262	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clinical Infectious Diseases, 2022, 75, e440-e449.	2.9	46
263	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	2.2	46
264	Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology, 2022, 88, 2065-2073.	1.1	55
265	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. International Journal of Molecular Sciences, 2021, 22, 11869.	1.8	16
268	COVID-19 Mechanisms in the Human Body—What We Know So Far. Frontiers in Immunology, 2021, 12, 693938.	2.2	40

#	ARTICLE	IF	CITATIONS
269	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
270	Rapid differential diagnosis of the B.1.617.2 (delta) variant of SARS-CoV-2 using an automated Cas12a microfluidic system. <i>Chemical Communications</i> , 2021, 57, 12270-12272.	2.2	8
271	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. <i>Immune Network</i> , 2021, 21, e32.	1.6	51
274	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	2.2	32
275	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 747830.	2.2	69
277	Molecular hydrogen as an adjuvant therapy may be associated with increased oxygen saturation and improved exercise tolerance in a COVID-19 patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05039.	0.2	10
278	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
279	Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab546.	0.4	6
281	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
282	Analysis of SARS-COV2 spike protein variants among Iraqi isolates. <i>Gene Reports</i> , 2022, 26, 101420.	0.4	12
283	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
285	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. <i>EBioMedicine</i> , 2021, 73, 103637.	2.7	19
286	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
288	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. <i>Infectious Diseases & Immunity</i> , 2022, 2, 29-33.	0.2	3
289	Genomic Surveillance Tracks the First Community Outbreak of the SARS-CoV-2 Delta (B.1.617.2) Variant in Brazil. <i>Journal of Virology</i> , 2022, 96, JVI0122821.	1.5	21
290	Marine mollusc extracts—Potential source of SARS-CoV-2 antivirals. <i>Reviews in Medical Virology</i> , 2022, 32, e2310.	3.9	2
291	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
292	Circulation and Evolution of SARS-CoV-2 in India: Let the Data Speak. <i>Viruses</i> , 2021, 13, 2238.	1.5	8

#	ARTICLE	IF	CITATIONS
293	Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. <i>Innovation(China)</i> , 2022, 3, 100181.	5.2	8
294	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	6.0	111
295	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
296	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26
297	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2 Naïve Residents of Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 75, e695-e704.	2.9	23
298	Ad26.CO2.S boosts antibody and T-cell responses following BNT162b2 vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 2220-2222.	3.0	2
299	Highly sensitive and specific detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse transcription PCR. <i>Journal of Clinical Virology</i> , 2022, 146, 105049.	1.6	15
300	Emergence of SARS-CoV-2 Delta Variant, Benin, May-July 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 205-209.	2.0	4
301	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. <i>Clinica Chimica Acta</i> , 2022, 524, 11-17.	0.5	16
302	Studies on Growth Characteristics and Cross-Neutralization of Wild-Type and Delta SARS-CoV-2 From Hisar (India). <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 771524.	1.8	5
304	Sleep Quality and the Depression-Anxiety-Stress State of Frontline Nurses Who Perform Nucleic Acid Sample Collection During COVID-19: A Cross-Sectional Study. <i>Psychology Research and Behavior Management</i> , 2021, Volume 14, 1889-1900.	1.3	13
305	Hotspot Mutations in SARS-CoV-2. <i>Frontiers in Genetics</i> , 2021, 12, 753440.	1.1	14
306	Alpha (B.1.1.7) and Delta (B.1.617.2 AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	4
307	SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant. <i>Microbiology Spectrum</i> , 2021, 9, e0112821.	1.2	4
308	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. <i>MBio</i> , 2021, , e0293621.	1.8	1
309	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19. <i>Vaccines</i> , 2021, 9, 1337.	2.1	28
310	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe, The</i> , 2022, 3, e52-e61.	3.4	436
312	Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. <i>Cell Host and Microbe</i> , 2021, 29, 1738-1743.e4.	5.1	61

#	ARTICLE	IF	CITATIONS
313	Long-term complications of COVID-19. American Journal of Physiology - Cell Physiology, 2022, 322, C1-C11.	2.1	201
314	Current Review of Delta Variant of SARS-CoV-2. European Journal of Medical and Health Sciences, 2021, 3, 23-29.	0.1	5
317	Elucidating important structural features for the binding affinity of spike α -SARS-CoV-2 neutralizing antibody complexes. Proteins: Structure, Function and Bioinformatics, 2022, 90, 824-834.	1.5	16
319	Differences in the case fatality risks associated with SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the United Kingdom. Infection, Genetics and Evolution, 2022, 97, 105162.	1.0	12
320	Immune response against SARS-CoV-2 variants: the role of neutralization assays. Npj Vaccines, 2021, 6, 142.	2.9	26
321	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. Viruses, 2021, 13, 2295.	1.5	13
322	PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio. Vaccines, 2021, 9, 1381.	2.1	26
323	Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Viruses, 2021, 13, 2405.	1.5	3
326	The danger of the single storyline obfuscating the complexities of managing SARS-CoV-2/COVID-19. Journal of Evaluation in Clinical Practice, 2022, 28, 1173-1186.	0.9	11
329	The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduction and Targeted Therapy, 2021, 6, 396.	7.1	111
330	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal of Experimental Medicine, 2022, 219, .	4.2	46
332	A Routine Sanger Sequencing Target Specific Mutation Assay for SARS-CoV-2 Variants of Concern and Interest. Viruses, 2021, 13, 2386.	1.5	8
334	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. Current Opinion in Pharmacology, 2022, 62, 64-73.	1.7	29
335	Complexity of immune responses in COVID-19. Seminars in Immunology, 2021, 55, 101545.	2.7	10
338	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. International Journal of Biological Macromolecules, 2021, 193, 1885-1897.	3.6	12
339	Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science, 2021, 28, 80.	2.6	17
340	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. Cells, 2021, 10, 3367.	1.8	42
341	Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. Journal of Medical Virology, 2022, 94, 1300-1314.	2.5	32

#	ARTICLE	IF	CITATIONS
343	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
344	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 273-278.	0.8	19
345	Neurological pathophysiology of SARS-CoV-2 and pandemic potential RNA viruses: a comparative analysis. <i>FEBS Letters</i> , 2021, 595, 2854-2871.	1.3	13
346	Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring. <i>Communications Biology</i> , 2021, 4, 1343.	2.0	27
348	Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin. <i>Virulence</i> , 2021, 12, 2946-2956.	1.8	12
349	Functionalized Nanoparticles in Prevention and Targeted Therapy of Viral Diseases With Neurotropism Properties, Special Insight on COVID-19. <i>Frontiers in Microbiology</i> , 2021, 12, 767104.	1.5	6
351	A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology. <i>Microbiology Spectrum</i> , 2021, 9, e0126721.	1.2	19
352	Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. <i>Molecules</i> , 2021, 26, 6900.	1.7	53
353	A review of epidemiology and public health control measures of COVID-19 variants in Hong Kong, December 2020 to June 2021. <i>IJID Regions</i> , 2022, 2, 16-24.	0.5	8
354	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
355	Advances in mRNA and other vaccines against MERS-CoV. <i>Translational Research</i> , 2022, 242, 20-37.	2.2	11
356	Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. <i>Cell Discovery</i> , 2021, 7, 112.	3.1	14
357	COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. <i>Healthcare (Switzerland)</i> , 2021, 9, 1566.	1.0	57
358	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. <i>Cancer Research</i> , 2021, 81, 6273-6280.	0.4	30
359	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100278.	3.0	109
360	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. <i>Nature</i> , 2022, 602, 300-306.	13.7	428
361	COVID-19 vaccines in the age of the delta variant. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 429-430.	4.6	6
364	High Mortality During the Second Wave of the Coronavirus Disease 2019 (COVID-19) Pandemic in Uganda: Experience From a National Referral COVID-19 Treatment Unit. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab530.	0.4	13

#	ARTICLE	IF	CITATIONS
365	Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases. <i>Infection</i> , 2021, , 1.	2.3	1
366	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
367	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	2.2	25
370	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
373	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 320-331.	1.9	90
374	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1681-1691.	5.1	118
376	Structural Analysis on the Severe Acute Respiratory Syndrome Coronavirus 2 Non-structural Protein 13 Mutants Revealed Altered Bonding Network With TANK Binding Kinase 1 to Evade Host Immune System. <i>Frontiers in Microbiology</i> , 2021, 12, 789062.	1.5	8
377	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
378	At-home testing to mitigate community transmission of SARS-CoV-2: protocol for a public health intervention with a nested prospective cohort study. <i>BMC Public Health</i> , 2021, 21, 2209.	1.2	17
379	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
380	Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine. <i>Infectious Diseases and Therapy</i> , 2022, 11, 351-365.	1.8	10
381	Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses. <i>Analytica Chimica Acta</i> , 2022, 1209, 339338.	2.6	24
382	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
383	Severe acute respiratory syndrome coronavirus 2 causes lung inflammation and injury. <i>Clinical Microbiology and Infection</i> , 2022, 28, 513-520.	2.8	12
385	Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 801-812.	2.6	40
386	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
387	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
388	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Host and Microbe</i> , 2022, 30, 97-109.e5.	5.1	83

#	ARTICLE	IF	CITATIONS
389	mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant. SSRN Electronic Journal, 0, , .	0.4	34
390	Recent Advances on Drugs and Vaccines for COVID-19. Inquiry (United States), 2021, 58, 004695802110556.	0.5	3
391	SARS-CoV-2 Lineage Tracking, and Evolving Trends Seen During Three Consecutive Peaks of Infection in Delhi, India – A Clinico-Genomic Study. SSRN Electronic Journal, 0, , .	0.4	2
392	Negative Troponin I as a Predictor of Survival in SARS-Cov-2 (COVID-19). SSRN Electronic Journal, 0, , .	0.4	0
393	Exploring the Bridge Cases™ Role in the Transmission of the SARS-CoV-2 Delta Variant – Ruili City, Yunnan Province, China, July–September 2021. China CDC Weekly, 2021, 3, 1065-1070.	1.0	5
394	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. Immune Network, 2021, 21, e39.	1.6	3
395	Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients. Frontiers in Medicine, 2021, 8, 792135.	1.2	42
396	Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles. Biosafety and Health, 2022, 4, 38-44.	1.2	7
398	SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody. Computers in Biology and Medicine, 2022, 142, 105226.	3.9	26
399	Genome Sequencing Reveals a Mixed Picture of SARS-CoV-2 Variant of Concern Circulation in Eastern Uttar Pradesh, India. Frontiers in Medicine, 2021, 8, 781287.	1.2	5
400	Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cellular and Molecular Immunology, 2022, 19, 293-295.	4.8	175
401	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology, 2022, 7, 277-288.	5.9	37
402	The dynamic change of SARS-CoV-2 variants in Sierra Leone. Infection, Genetics and Evolution, 2022, 98, 105208.	1.0	5
403	Omicron, the great escape artist. Nature Reviews Immunology, 2022, 22, 75-75.	10.6	87
404	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Reports, 2022, 38, 110210.	2.9	96
405	Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19. Cureus, 2022, 14, e20980.	0.2	5
408	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences (Switzerland), 2022, 12, 665.	1.3	8
410	Probing the formation, structure and free energy relationships of M protein dimers of SARS-CoV-2. Computational and Structural Biotechnology Journal, 2022, 20, 573-582.	1.9	9

#	ARTICLE	IF	CITATIONS
411	The benefits, costs and feasibility of a low incidence COVID-19 strategy. <i>Lancet Regional Health - Europe, The</i> , 2022, 13, 100294.	3.0	17
412	High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. <i>Emerging Infectious Diseases</i> , 2022, 28, 491-492.	2.0	0
413	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. <i>European Journal of Cancer</i> , 2022, 162, 182-193.	1.3	40
414	A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding. <i>Immunology Letters</i> , 2022, 242, 1-7.	1.1	4
415	Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017â€“2020: a multicenter, retrospective cohort study in Japan. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 20, 100365.	1.3	28
416	A fractal scaling analysis of the SARS-CoV-2 genome sequence. <i>Biomedical Signal Processing and Control</i> , 2022, 73, 103433.	3.5	4
417	Whole-Genome Sequences Analysis Displays Relationship of SARS-CoV-2 Delta Variant Between Four Local Cases and Passengers of a Flight from South Africa â€” Shenzhen City, Guangdong Province, China, June 2021. <i>China CDC Weekly</i> , 2021, 3, 1075-1078.	1.0	0
418	Active site-specific quantum tunneling of hACE2 receptor to assess its complexing poses with selective bioactive compounds in co-suppressing SARS-CoV-2 influx and subsequent cardiac injury. <i>Journal of Advanced Veterinary and Animal Research</i> , 2021, 8, 1.	0.5	13
419	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
420	Antigenic Map of SARS-CoV-2 Variants Including Omicron. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
421	Primer of COVID-19 Vaccines for the Perioperative Physician. <i>Journal of Neurosurgical Anesthesiology</i> , 2022, 34, 101-106.	0.6	0
422	Delta variant of SARS-CoV-2: characteristics and implications for public health in Colombia. <i>Revista Facultad De Medicina</i> , 2021, 70, e97460.	0.0	1
423	Rejoinder: Regression Models for Understanding COVID-19 Epidemic Dynamics With Incomplete Data. <i>Journal of the American Statistical Association</i> , 2021, 116, 1591-1594.	1.8	1
427	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 2022, 602, 671-675.	13.7	1,202
429	Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variantâ€™s Superior Transmission. <i>International Journal of Molecular Sciences</i> , 2022, 23, 796.	1.8	10
430	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. <i>Nature Medicine</i> , 2022, 28, 496-503.	15.2	215
431	Immunological challenges of the â€œnewâ€•infections: corona viruses. , 2022, , 395-450.		2
432	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. <i>Med</i> , 2022, 3, 28-41.e8.	2.2	19

#	ARTICLE	IF	CITATIONS
433	Great Expectations of COVID-19 Herd Immunity. MBio, 2022, 13, e0349521.	1.8	9
434	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. Microorganisms, 2022, 10, 268.	1.6	12
435	Serological Markers of SARS-CoV-2 Reinfection. MBio, 2022, 13, e0214121.	1.8	8
436	The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. Inflammopharmacology, 2022, 30, 149-157.	1.9	3
437	SARS-CoV-2 Virology. Infectious Disease Clinics of North America, 2022, 36, 251-265.	1.9	7
439	SARS-CoV-2 neutralizing activity of polyphenols in a special green tea extract preparation. Phytomedicine, 2022, 98, 153970.	2.3	23
440	Healthcare Innovations to Address the Challenges of the COVID-19 Pandemic. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 3294-3302.	3.9	13
441	Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	54
442	Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nature Communications, 2022, 13, 460.	5.8	304
443	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675.	1.7	3
444	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. Journal of Hematology and Oncology, 2022, 15, 5.	6.9	30
445	COVID-19: Les thérapeutiques. , 2022, 1, 13-13.		0
446	Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women. Vaccines, 2022, 10, 101.	2.1	23
447	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	6.0	91
448	Modeling the Transmission of the SARS-CoV-2 Delta Variant in a Partially Vaccinated Population. Viruses, 2022, 14, 158.	1.5	6
449	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Annals of the Rheumatic Diseases, 2022, 81, 720-728.	0.5	39
450	COVID-19 Pandemic and Periodontal Practice: The Immunological, Clinical, and Economic Points of View. BioMed Research International, 2022, 2022, 1-10.	0.9	4
453	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. Frontiers in Immunology, 2021, 12, 785349.	2.2	7

#	ARTICLE	IF	CITATIONS
454	Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel. <i>Frontiers in Medicine</i> , 2021, 8, 836658.	1.2	4
457	Rapid testing for coronavirus disease 2019 (COVID-19). <i>MRS Communications</i> , 2022, 12, 12-23.	0.8	13
458	The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 143-146.	1.1	27
459	T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. <i>Cellular and Molecular Immunology</i> , 2022, 19, 447-448.	4.8	68
460	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
461	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	15.2	342
462	Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant. <i>Pathology</i> , 2022, 54, 351-356.	0.3	13
463	Contact tracing period and epidemiological characteristics of an outbreak of the SARS-CoV-2 Delta variant in Guangzhou. <i>International Journal of Infectious Diseases</i> , 2022, 117, 18-23.	1.5	8
464	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
465	Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. <i>Vaccines</i> , 2022, 10, 154.	2.1	8
466	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
469	SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household. <i>Journal of Korean Medical Science</i> , 2022, 37, e12.	1.1	18
470	Complex Contact Network of Patients at the Beginning of an Epidemic Outbreak: An Analysis Based on 1218 COVID-19 Cases in China. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 689.	1.2	9
471	Nanoagent-based theranostic strategies against human coronaviruses. <i>Nano Research</i> , 2022, 15, 1-15.	5.8	4
472	Update to COVID-19 serologic testing : FAQs and caveats. <i>Cleveland Clinic Journal of Medicine</i> , 2022, , .	0.6	3
473	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. <i>Cell Host and Microbe</i> , 2022, 30, 69-82.e10.	5.1	42
474	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	1.5	1
476	A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers. <i>Communications Medicine</i> , 2022, 2, .	1.9	12

#	ARTICLE	IF	CITATIONS
477	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. <i>MBio</i> , 2022, 13, e0323821.	1.8	11
480	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. <i>Life</i> , 2022, 12, 194.	1.1	25
481	Modeling and optimal control of mutated COVID-19 (Delta strain) with imperfect vaccination. <i>Chaos, Solitons and Fractals</i> , 2022, 156, 111825.	2.5	41
483	Will the COVID-19 pandemic end with the Delta and Omicron variants?. <i>Environmental Chemistry Letters</i> , 2022, 20, 2215-2225.	8.3	36
485	Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. <i>Annals of Internal Medicine</i> , 2022, 175, 455-456.	2.0	98
486	Equitable access to COVID-19 vaccines makes a life-saving difference to all countries. <i>Nature Human Behaviour</i> , 2022, 6, 207-216.	6.2	85
487	Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 64-65.	1.4	2
488	Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants. <i>Epidemiology and Infection</i> , 2022, 150, 1-22.	1.0	9
489	SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron. <i>Frontiers in Immunology</i> , 2022, 13, 801431.	2.2	31
490	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <i>Cell</i> , 2022, 185, 457-466.e4.	13.5	881
491	Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. <i>Cell Reports</i> , 2022, 38, 110394.	2.9	9
492	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
493	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2022, 375, .	6.0	68
494	Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19. <i>Viruses</i> , 2022, 14, 94.	1.5	7
497	Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination. <i>European Journal of Immunology</i> , 2022, 52, 356-359.	1.6	7
498	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
500	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
501	Crucial control measures to contain China's first Delta variant outbreak. <i>National Science Review</i> , 2022, 9, nwac004.	4.6	7

#	ARTICLE	IF	CITATIONS
502	Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?. <i>Vox Sanguinis</i> , 2022, 117, 641-646.	0.7	8
503	Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. <i>Current Research in Virological Science</i> , 2022, 3, 100019.	1.8	20
504	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. <i>ELife</i> , 2022, 11, .	2.8	19
505	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0218421.	1.5	14
506	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. <i>Lancet, The</i> , 2022, 399, 25-35.	6.3	109
507	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
509	Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. <i>MABs</i> , 2022, 14, 2021601.	2.6	11
510	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120
511	Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. <i>Journal of Immunology</i> , 2022, 208, 1139-1145.	0.4	10
512	Is Omicron the last SARS-CoV-2 Variant of Concern?. <i>Archives of Medical Research</i> , 2022, 53, 336-338.	1.5	12
513	An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines. <i>Vaccine</i> , 2022, 40, 1208-1212.	1.7	3
514	Testing strategies to contain COVID-19 in migrant worker dormitories. <i>Journal of Migration and Health</i> , 2022, 5, 100079.	1.6	2
515	Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12179.	5.5	24
517	Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. <i>Frontiers in Immunology</i> , 2021, 12, 808047.	2.2	4
519	New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210755.	0.7	85
520	SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. <i>JAMA Oncology</i> , 2022, 8, 612.	3.4	35
521	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. <i>Life</i> , 2022, 12, 57.	1.1	6
523	Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. <i>EMBO Molecular Medicine</i> , 2022, 14, e15227.	3.3	31

#	ARTICLE	IF	CITATIONS
525	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
526	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 37.	0.9	2
527	Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 830527.	2.2	165
529	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	2.7	104
530	VirusClust: direct comparison of SARS-CoV-2 genomes and genetic variants in space and time. <i>Bioinformatics</i> , 2022, 38, 1988-1994.	1.8	9
531	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. <i>Life</i> , 2022, 12, 130.	1.1	1
532	Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. <i>Medical Microbiology and Immunology</i> , 2022, 211, 71-77.	2.6	25
533	Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent 1-year global expansion. <i>Journal of Medical Virology</i> , 2022, 94, 2035-2049.	2.5	7
534	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	5.8	92
535	Neonatal acute ethanol intoxication during the epidemic of COVID-19: a case report. <i>BMC Pediatrics</i> , 2022, 22, 53.	0.7	2
536	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. <i>Viruses</i> , 2022, 14, 144.	1.5	12
537	Modeling the omicron wave in France in early 2022: Balancing herd immunity with protecting the most vulnerable. <i>Journal of Travel Medicine</i> , 2022, , .	1.4	6
538	Humoral immune response after different SARS-CoV-2 vaccination regimens. <i>BMC Medicine</i> , 2022, 20, 31.	2.3	47
539	<sc>SARS-CoV</sc> Delta variant in Cartagena de Indias, Colombia, August 2021. <i>Health Science Reports</i> , 2022, 5, e480.	0.6	0
540	Differential COVID-19 Symptoms Given Pandemic Locations, Time, and Comorbidities During the Early Pandemic. <i>Frontiers in Medicine</i> , 2022, 9, 770031.	1.2	10
541	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
542	Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 995-998.	13.9	301
543	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	1.5	1

#	ARTICLE	IF	CITATIONS
544	SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. <i>Frontiers in Immunology</i> , 2022, 13, 825256.	2.2	54
546	Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 225.	2.1	6
547	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 824-837.	1.9	49
548	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
550	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	13.9	102
551	Repurposing of approved drugs and nutraceuticals to identify potential inhibitors of SARS-CoV-2 entry into human host cells: a structural analysis using induced-fit docking, MMGBSA and molecular dynamics simulation approach. <i>Molecular Simulation</i> , 2022, 48, 367-386.	0.9	3
554	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
556	Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. <i>Mayo Clinic Proceedings</i> , 2022, 97, 327-332.	1.4	17
557	Predictors of Nonseroconversion after SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2022, 28, 492-493.	2.0	1
558	SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. <i>FEBS Journal</i> , 2022, 289, 4240-4250.	2.2	25
559	Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. <i>Journal of Clinical Virology</i> , 2022, 147, 105080.	1.6	28
560	CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant. <i>Viruses</i> , 2022, 14, 305.	1.5	2
561	An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102396.	1.8	51
562	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
563	Human Organoids and Organ-on-a-Chips for Addressing COVID-19 Challenges. <i>Advanced Science</i> , 2022, 9, e2105187.	5.6	19
564	Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. <i>ChemBioChem</i> , 2022, 23, e202100681.	1.3	62
565	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. <i>Infection</i> , 2022, , 1.	2.3	15
566	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	1.9	56

#	ARTICLE	IF	CITATIONS
568	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
569	SARS-CoV-2 multiplex RT-PCR to detect variants of concern (VOCs) in Malaysia, between January to May 2021. Journal of Virological Methods, 2022, 301, 114462.	1.0	25
570	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. Virus Research, 2022, 310, 198674.	1.1	24
571	Decreased risk of COVID-19 pneumonia in children and adolescents during the Delta variant emergence. Public Health, 2022, 204, 9-11.	1.4	6
572	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environmental Research, 2022, 209, 112816.	3.7	189
573	SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis. Informatics in Medicine Unlocked, 2022, 29, 100873.	1.9	1
574	Aerosolized Nanobodies Prevent Infections of SARS-CoV-2 in PrEP and PEP Settings in Mice and are Effective to Variants. SSRN Electronic Journal, 0, , .	0.4	0
575	Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates. Journal of Medical Virology, 2022, 94, 2336-2342.	2.5	75
577	A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Molecular Medicine, 2022, 14, e15298.	3.3	23
579	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology, 2022, 7, 423-433.	5.9	78
580	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. Journal of Clinical Investigation, 2022, 132, .	3.9	30
581	Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?. Paediatric Respiratory Reviews, 2022, 44, 61-69.	1.2	6
583	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. Molecular Diversity, 2022, 26, 3309-3324.	2.1	17
584	Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. Antibodies, 2022, 11, 13.	1.2	6
585	Infection and pathogenesis of the Delta variant of SARS-CoV-2 in Rhesus macaque. Virologica Sinica, 2022, , .	1.2	4
588	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. Medicina (Lithuania), 2022, 58, 261.	0.8	3
589	Composition, Clinical Efficiency, and Mechanism of NHC-Approved "Three Chinese Medicines and Three Chinese Recipes" for COVID-19 Treatment. Frontiers in Pharmacology, 2021, 12, 781090.	1.6	14
591	Structure Guided Design of Bacteriophage Q β Mutants as Next Generation Carriers for Conjugate Vaccines. ACS Chemical Biology, 2022, 17, 3047-3058.	1.6	10

#	ARTICLE	IF	CITATIONS
592	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. <i>Science</i> , 2022, 375, 678-680.	6.0	303
593	Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants. <i>Transfusion</i> , 2022, 62, 563-569.	0.8	7
594	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, 811004.	1.2	3
596	Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. <i>Molecular Therapy</i> , 2022, 30, 1979-1993.	3.7	15
597	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
598	Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 23-31.	1.9	17
599	Advanced Materials for SARS-CoV-2 Vaccines. <i>Advanced Materials</i> , 2022, 34, e2107781.	11.1	25
600	Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. <i>Viruses</i> , 2022, 14, 351.	1.5	11
602	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. <i>BMC Medicine</i> , 2022, 20, 52.	2.3	7
603	Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 942-946.	0.6	24
604	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	5.6	12
606	Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 816429.	1.6	7
607	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 742.	5.8	71
608	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
609	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
610	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Reports</i> , 2022, 38, 110429.	2.9	50
611	Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?. <i>Vaccines</i> , 2022, 10, 248.	2.1	1
612	The Coronavirus pandemic - 2022: Viruses, variants & vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 1-9.	3.2	31

#	ARTICLE	IF	CITATIONS
613	COVID-19 vaccination and breakthrough infections in patients with cancer. <i>Annals of Oncology</i> , 2022, 33, 340-346.	0.6	76
615	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
619	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
620	Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. <i>Antiviral Research</i> , 2021, 196, 105197.	1.9	15
621	Rapid characterization of spike variants via mammalian cell surface display. <i>Molecular Cell</i> , 2021, 81, 5099-5111.e8.	4.5	32
622	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 0, , .	13.7	88
623	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. <i>Nature Communications</i> , 2021, 12, 7345.	5.8	58
624	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
625	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
626	SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	52
627	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. <i>Clinical and Experimental Immunology</i> , 2022, 207, 263-271.	1.1	14
628	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e683-e691.	2.9	48
629	Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. <i>Clinical Infectious Diseases</i> , 2022, 75, e715-e725.	2.9	130
630	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	1.9	65
647	Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). <i>Science Advances</i> , 2021, 7, eabk0172.	4.7	32
648	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
649	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. <i>MBio</i> , 2021, 12, e0334721.	1.8	45
650	Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. <i>Microbiology Spectrum</i> , 2021, 9, e0137621.	1.2	22

#	ARTICLE	IF	CITATIONS
651	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. <i>PLoS Pathogens</i> , 2021, 17, e1010175.	2.1	15
652	A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World. , 2022, 13, 927.		11
653	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
654	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. <i>Microorganisms</i> , 2021, 9, 2622.	1.6	9
655	Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis. <i>Pathogens</i> , 2022, 11, 45.	1.2	44
656	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	1.5	23
657	Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing. <i>Viruses</i> , 2021, 13, 2544.	1.5	12
658	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. <i>Vaccines</i> , 2021, 9, 1442.	2.1	18
659	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2021, , eabl6251.	6.0	12
660	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2021, , eabm0811.	6.0	10
661	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
662	Effectiveness of mRNA COVID-19 Vaccines in Japan during the Nationwide Pandemic of the Delta Variant. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 257, 1-6.	0.5	6
663	Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 116.	1.1	3
664	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	1.3	7
665	The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia. <i>Virus Evolution</i> , 2022, 8, veac017.	2.2	24
666	An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages. <i>Theranostics</i> , 2022, 12, 2639-2657.	4.6	19
667	Impaired Humoral Immunity Is Associated With Prolonged COVID-19 Despite Robust CD8 T-Cell Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
668	Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study. <i>Infection and Chemotherapy</i> , 2022, 54, 91.	1.0	9

#	ARTICLE	IF	CITATIONS
669	Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic. <i>Journal of Korean Medical Science</i> , 2022, 37, e67.	1.1	3
670	AI-powered drug repurposing for developing COVID-19 treatments. , 2024, , 144-154.		4
671	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
672	Replacement of the Gamma by the Delta variant in Brazil: Impact of lineage displacement on the ongoing pandemic. <i>Virus Evolution</i> , 2022, 8, veac024.	2.2	37
673	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
674	Effectiveness of the emergency public activity restrictions on COVID-19 epidemiological parameter in East Java Province, Indonesia: An ecological study. <i>Asian Journal of Social Health and Behavior</i> , 2022, 5, 33.	2.0	19
675	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
676	Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea. <i>Infection and Chemotherapy</i> , 2022, 54, 114.	1.0	11
677	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, 17.	3.1	23
678	Population antibody responses following COVID-19 vaccination in 212,102 individuals. <i>Nature Communications</i> , 2022, 13, 907.	5.8	94
679	Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac093.	0.4	3
681	Vaccines alone will not prevent COVID-19 outbreaks among migrant workers—the example of meat processing plants. <i>Clinical Microbiology and Infection</i> , 2022, 28, 773-778.	2.8	13
682	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. <i>Microbiology Spectrum</i> , 2022, 10, e0226221.	1.2	5
683	Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil. <i>Microbiology Spectrum</i> , 2022, 10, e0236621.	1.2	28
684	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. <i>Journal of Infection</i> , 2022, 84, 171-178.	1.7	25
686	Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery. <i>Medicinal Chemistry</i> , 2022, 18, 847-858.	0.7	3
687	The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. <i>Frontiers in Immunology</i> , 2022, 13, 833715.	2.2	7
688	Global impact of delta plus variant and vaccination. <i>Expert Review of Vaccines</i> , 2022, 21, 597-600.	2.0	41

#	ARTICLE	IF	CITATIONS
689	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€™BioNTech) in Patients on Hemodialysis. <i>Vaccines</i> , 2022, 10, 327.	2.1	7
692	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
696	Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. <i>Nature Communications</i> , 2022, 13, 864.	5.8	72
698	COVID-19 can be called a treatable disease only after we have antivirals. <i>Science Bulletin</i> , 2022, 67, 999-1002.	4.3	5
699	In-Flight Transmission of a SARS-CoV-2 Lineage B.1.617.2 Harboring the Rare S:E484Q Immune Escape Mutation. <i>Viruses</i> , 2022, 14, 504.	1.5	2
700	Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Proteinâ€™Ligand Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2392.	1.8	3
701	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 824851.	1.8	51
702	Neutralization of SARS-CoV-2 Variants by rVSV-Î³G-Spike-Elicited Human Sera. <i>Vaccines</i> , 2022, 10, 291.	2.1	19
703	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	2.9	64
704	Trained Immunity: An Overview and the Impact on COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 837524.	2.2	35
705	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
706	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. <i>ELife</i> , 2022, 11, .	2.8	26
707	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. <i>Nature Communications</i> , 2022, 13, 871.	5.8	107
708	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. <i>Npj Vaccines</i> , 2022, 7, 24.	2.9	18
709	Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2078.	1.8	5
710	Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 822159.	2.2	19
711	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	15.2	147
712	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1073-1076.	2.6	44

#	ARTICLE	IF	CITATIONS
714	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. <i>Microbiology Spectrum</i> , 2022, 10, e0169521.	1.2	8
715	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
716	Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. <i>Cell Research</i> , 2022, 32, 401-403.	5.7	37
717	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
718	Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants. <i>Journal of the American Chemical Society</i> , 2022, 144, 5702-5707.	6.6	24
719	Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. <i>PLoS ONE</i> , 2022, 17, e0257930.	1.1	12
720	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. <i>Vaccines</i> , 2022, 10, 508.	2.1	5
721	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
722	Computational Investigations for Identification of Bioactive Molecules from <i>Baccaurea ramiflora</i> and <i>Bergenia ciliata</i> as Inhibitors of SARS-CoV-2 M ^{pro} . <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 2459-2487.	1.4	25
723	Assessing the Transmissibility of the New SARS-CoV-2 Variants: From Delta to Omicron. <i>Vaccines</i> , 2022, 10, 496.	2.1	9
724	SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	7
725	The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals. <i>Vaccine</i> , 2022, 40, 1928-1931.	1.7	5
726	Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells. <i>Virologica Sinica</i> , 2022, 37, 380-389.	1.2	10
727	Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern. <i>Scientific Reports</i> , 2022, 12, 3954.	1.6	2
729	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). <i>Frontiers in Immunology</i> , 2022, 13, 865401.	2.2	8
730	Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. <i>Frontiers in Medical Technology</i> , 2022, 4, 867982.	1.3	11
731	The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines. <i>Health Policy and Technology</i> , 2022, 11, 100619.	1.3	7
732	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. <i>Frontiers in Microbiology</i> , 2022, 13, 763169.	1.5	3

#	ARTICLE	IF	CITATIONS
733	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 863039.	2.2	10
735	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2122954119.	3.3	57
737	Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. <i>Microbiology Spectrum</i> , 2022, 10, e0225221.	1.2	9
738	Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants. <i>MAbs</i> , 2022, 14, 2040350.	2.6	6
740	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
741	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. <i>MBio</i> , 2022, 13, e0009922.	1.8	22
742	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. <i>Frontiers in Immunology</i> , 2022, 13, 835104.	2.2	28
744	Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. <i>ESMO Open</i> , 2022, 7, 100458.	2.0	18
745	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100603.	3.3	27
746	Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic. <i>Genes</i> , 2022, 13, 552.	1.0	13
747	Mapping Data to Deep Understanding: Making the Most of the Deluge of SARS-CoV-2 Genome Sequences. <i>MSystems</i> , 2022, 7, e0003522.	1.7	5
749	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. <i>EBioMedicine</i> , 2022, 77, 103934.	2.7	10
750	Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?. <i>Journal of Virology</i> , 2022, 96, jvi0207721.	1.5	143
751	Mutations and Evolution of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 640.	1.5	111
752	Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. <i>International Journal of Infectious Diseases</i> , 2022, 119, 69-76.	1.5	48
753	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
754	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
755	Can anti-parasitic drugs help control COVID-19?. <i>Future Virology</i> , 2022, 17, 315-339.	0.9	5

#	ARTICLE	IF	CITATIONS
756	Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1785.	3.3	13
757	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
758	The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine. <i>Vaccines</i> , 2022, 10, 536.	2.1	14
759	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
761	Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 157-169.e10.	1.5	5
762	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
763	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	6.0	651
764	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
765	Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. <i>Nature Immunology</i> , 2022, 23, 543-555.	7.0	185
767	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. <i>Frontiers in Immunology</i> , 2022, 13, 797589.	2.2	30
768	Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China. <i>Frontiers in Public Health</i> , 2022, 10, 834572.	1.3	18
769	Advances in the Omicron variant development. <i>Journal of Internal Medicine</i> , 2022, 292, 81-90.	2.7	85
770	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
771	SARS-CoV-2 spike E156G/I ¹⁵⁷⁻¹⁵⁸ mutations contribute to increased infectivity and immune escape. <i>Life Science Alliance</i> , 2022, 5, e202201415.	1.3	24
772	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	14
773	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
775	Circulation of SARS-CoV-2 Variants among Children from November 2020 to January 2022 in Trieste (Italy). <i>Microorganisms</i> , 2022, 10, 612.	1.6	8
776	Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	5

#	ARTICLE	IF	CITATIONS
777	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204521.	1.4	6
778	Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody. <i>PLoS ONE</i> , 2022, 17, e0266250.	1.1	7
779	Global trends in COVID-19. , 2022, 1, 31-39.		8
781	Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 802-805.	0.8	18
782	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	5.6	22
783	Understanding T cell responses to COVID-19 is essential for informing public health strategies. <i>Science Immunology</i> , 2022, 7, eabo1303.	5.6	87
784	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. <i>Viruses</i> , 2022, 14, 549.	1.5	13
785	The Successes and Challenges of SARS-CoV-2 Molecular Testing in the United States. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 147-160.	0.7	6
786	Implications of evolutionary unpredictability for gain-of-function research. <i>Postgraduate Medical Journal</i> , 2022, , postgradmedj-2022-141612.	0.9	0
787	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
789	Management of the wound care clinic during the novel coronavirus pneumonia pandemic period: Sharing of management experience in a general hospital of China. <i>International Wound Journal</i> , 2022, , .	1.3	0
790	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. <i>Microbiology Spectrum</i> , 2022, 10, e0270221.	1.2	3
791	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
792	SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic. <i>Chemical Biology and Drug Design</i> , 2022, 99, 769-788.	1.5	37
793	A multipeptide SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	49
794	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. <i>Inflammation Research</i> , 2022, 71, 377-396.	1.6	11
795	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 914-925.	3.0	8
796	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235

#	ARTICLE	IF	CITATIONS
797	Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India. <i>International Journal of Infectious Diseases</i> , 2022, 119, 111-113.	1.5	1
798	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.4	25
799	mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. <i>Cell Reports</i> , 2022, 39, 110680.	2.9	21
800	Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease. <i>Small Science</i> , 2022, 2, .	5.8	17
801	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
802	A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2022, 77, 351-362.	0.6	7
803	SARS-CoV-2 Lineage Tracking, and Evolving Trends Seen during Three Consecutive Peaks of Infection in Delhi, India: a Clinico-Genomic Study. <i>Microbiology Spectrum</i> , 2022, 10, e0272921.	1.2	5
804	Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach. <i>Indian Journal of Medical Microbiology</i> , 2022, 40, 413-419.	0.3	1
805	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
806	Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. <i>Clinical Microbiology and Infection</i> , 2022, 28, 596-601.	2.8	3
807	Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection. <i>Small</i> , 2022, 18, e2200125.	5.2	6
809	Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119467119.	3.3	25
810	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
812	Micronutrients to Support Vaccine Immunogenicity and Efficacy. <i>Vaccines</i> , 2022, 10, 568.	2.1	10
813	Molecular epidemiological features of SARS-CoV-2 in Japan, 2020-2021. <i>Virus Evolution</i> , 2022, 8, veac034.	2.2	9
814	Timing the race of vaccination, new variants, and relaxing restrictions during COVID-19 pandemic. <i>Journal of Computational Science</i> , 2022, 61, 101660.	1.5	12
816	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	5.8	30
817	Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816389.	2.2	5

#	ARTICLE	IF	CITATIONS
818	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
819	A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	4
820	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. <i>Clinical Immunology</i> , 2022, 238, 108999.	1.4	10
821	In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. <i>JCI Insight</i> , 2022, 7, .	2.3	9
822	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. <i>Reviews in Medical Virology</i> , 2022, 32, e2347.	3.9	7
823	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
824	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. <i>Cell</i> , 2022, 185, 1875-1887.e8.	13.5	148
825	Modeling COVID-19 dynamic using a two-strain model with vaccination. <i>Chaos, Solitons and Fractals</i> , 2022, 157, 111927.	2.5	26
826	Combatting future variants of SARS-CoV-2 using an in-silico peptide vaccine approach by targeting the spike protein. <i>Medical Hypotheses</i> , 2022, 161, 110810.	0.8	5
827	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
828	Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4050.	1.8	17
830	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. <i>Chinese Medicine</i> , 2022, 17, 40.	1.6	8
831	High viral loads: what drives fatal cases of COVID-19 in vaccinees? – an autopsy study. <i>Modern Pathology</i> , 2022, 35, 1013-1021.	2.9	5
832	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
834	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
835	Equine immunoglobulin fragment F(ab [™]) ₂ displays high neutralizing capability against multiple SARS-CoV-2 variants. <i>Clinical Immunology</i> , 2022, 237, 108981.	1.4	2
836	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 499-502.	1.0	10
838	Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. <i>Vaccine: X</i> , 2022, 10, 100153.	0.9	25

#	ARTICLE	IF	CITATIONS
841	New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality. Exploration of Immunology, 0, , 432-439.	1.7	0
844	Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 3-5.	2.2	1
847	Vaccination Against COVID-19: Emerging Issues and Future Prospects. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 652-660.	0.2	1
850	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. Viruses, 2022, 14, 69.	1.5	5
852	Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population. Vaccines, 2021, 9, 1459.	2.1	11
853	Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice. Signal Transduction and Targeted Therapy, 2021, 6, 419.	7.1	8
854	Capturing adaptive immunity against SARS-CoV-2 in patients with cancer. Nature Cancer, 2021, 2, 1298-1300.	5.7	2
855	Use of simplified models for theoretical prediction of the interactions between available antibodies and the receptor-binding domain of SARS-CoV-2 spike protein. Journal of Biomolecular Structure and Dynamics, 2021, , 1-10.	2.0	1
857	HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Reports, 2021, 37, 110167.	2.9	18
859	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. Transactions of the Royal Society of South Africa, 0, , 1-4.	0.8	2
863	SARS-CoV-2 Variants: Mutations and Effective Changes. Biotechnology and Bioprocess Engineering, 2021, 26, 859-870.	1.4	12
865	A Framework for Crowd Management during COVID-19 with Artificial Intelligence. Sustainability, 2022, 14, 303.	1.6	17
866	Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infectious Diseases, 2022, 9, ofab632.	0.4	30
867	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. Frontiers in Immunology, 2021, 12, 789905.	2.2	7
869	Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges. Journal of Medical Virology, 2022, 94, 1373-1390.	2.5	35
870	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. Cells, 2022, 11, 67.	1.8	7
871	Characteristics of Elderly Patients Who Require Oxygen Therapy. Korean Journal of Clinical Geriatrics, 2021, 22, 75-85.	0.3	0
872	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. 3 Biotech, 2022, 12, 15.	1.1	20

#	ARTICLE	IF	CITATIONS
873	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
876	The twin-beginnings of COVID-19 in Asia and Europe – one prevails quickly. <i>National Science Review</i> , 2022, 9, nwab223.	4.6	22
879	Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China. <i>Bioanalysis</i> , 2021, 13, 1731-1741.	0.6	1
881	COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance. <i>Vaccines</i> , 2021, 9, 1474.	2.1	6
883	Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13202.	1.8	20
885	Sociodemographic Disparities In Access To COVID-19 Vaccines Upon Initial Rollout In Florida. <i>Health Affairs</i> , 2021, 40, 1883-1891.	2.5	6
886	Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 1893-1905.	2.5	11
887	Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 January – 2 July 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e267-e275.	2.9	12
888	Demographic Features of COVID-19 in Two Waves in A Single Center. <i>Journal of Microbiology and Infectious Diseases</i> , 0, , 174-182.	0.1	0
889	The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05028.	1.2	4
890	Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. <i>Frontiers in Immunology</i> , 2021, 12, 793191.	2.2	16
892	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. , 2021, , .		5
893	Chimeric crRNA improves CRISPR-Cas12a specificity in the N501Y mutation detection of Alpha, Beta, Gamma, and Mu variants of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0261778.	1.1	6
894	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
895	Evolution of enhanced innate immune evasion by SARS-CoV-2. <i>Nature</i> , 2022, 602, 487-495.	13.7	237
899	Epidemiology of COVID-19: An updated review. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 82.	0.4	12
900	In silico Identification of a Viral Surface Glycoprotein Site Suitable for the Development of Low Molecular Weight Inhibitors for Various Variants of the SARS-CoV-2. <i>Mikrobiologichnyĭ Zhurnal</i> , 2021, 84, 34-43.	0.2	1
901	On the Delta Plus Variant of SARS-CoV-2. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 52-55.	0.1	2

#	ARTICLE	IF	CITATIONS
902	Persistent Maintenance of Atypical Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. SSRN Electronic Journal, 0, , .	0.4	0
903	Evaluation of a Rapid Semiquantitative Lateral Flow Assay for the Prediction of Serum Neutralizing Activity Against SARS-CoV-2 Variants. SSRN Electronic Journal, 0, , .	0.4	0
904	Coronavirus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 101-121.	0.8	3
905	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. Age and Ageing, 2022, 51, .	0.7	7
906	A Safe Pseudotyped Lentivirus-Based Assay to Titer SARS-CoV-2 Neutralizing Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
907	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Science Translational Medicine, 2022, 14, eabm2311.	5.8	100
908	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. Frontiers in Immunology, 2022, 13, 857440.	2.2	15
909	Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. Biomolecules, 2022, 12, 572.	1.8	8
910	Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. International Journal of Molecular Sciences, 2022, 23, 4376.	1.8	16
913	US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response. Clinical Infectious Diseases, 2022, 75, 1940-1949.	2.9	3
914	DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2. BMC Genomics, 2022, 23, 289.	1.2	5
915	Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Reports, 2022, 39, 110786.	2.9	37
916	Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19. Frontiers in Immunology, 2022, 13, 868020.	2.2	3
917	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. Viruses, 2022, 14, 827.	1.5	14
918	Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. American Journal of Obstetrics and Gynecology, 2022, 227, 486.e1-486.e10.	0.7	7
919	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
921	Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	14
922	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5

#	ARTICLE	IF	CITATIONS
923	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. <i>Cell Research</i> , 2022, 32, 593-595.	5.7	55
924	Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection. <i>Microbes and Infection</i> , 2022, 24, 104979.	1.0	8
926	Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. <i>Vaccines</i> , 2022, 10, 580.	2.1	2
927	Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	8
928	Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: A mathematical modeling study. <i>Journal of Medical Virology</i> , 2022, 94, 3722-3730.	2.5	4
929	Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination. <i>Vaccines</i> , 2022, 10, 636.	2.1	0
930	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <i>Scientia Pharmaceutica</i> , 2022, 90, 24.	0.7	7
932	Reverse vaccinology approach for multi-epitope centered vaccine design against delta variant of the SARS-CoV-2. <i>Environmental Science and Pollution Research</i> , 2022, 29, 60035-60053.	2.7	13
933	Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability. <i>Journal of Physical Chemistry B</i> , 2022, 126, 2812-2823.	1.2	11
934	Large Scale SARS-CoV-2 Molecular Testing and Genomic Surveillance Reveal Prolonged Infections, Protracted RNA shedding, and Viral Reinfections. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 809407.	1.8	6
935	Multistage-Split Ultrafine Fluffy Nanofibrous Membrane for High-Efficiency Antibacterial Air Filtration. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 18989-19001.	4.0	42
936	Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105161.	1.6	8
937	Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105162.	1.6	7
938	Comparison between an in-house SARS-CoV-2 ELISpot and the T-Spot®-Discovery SARS-CoV-2 for the assessment of T cell responses in prior SARS-CoV-2-infected individuals. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105158.	1.6	0
939	Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals. <i>Bioorganic Chemistry</i> , 2022, 124, 105799.	2.0	4
940	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. <i>EBioMedicine</i> , 2022, 78, 103944.	2.7	119
941	Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0017822.	1.8	15
942	Anti-SARS-CoV-2 potential of <i>Cissampelos pareira</i> L. identified by connectivity map-based analysis and in vitro studies. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 114.	1.2	4

#	ARTICLE	IF	CITATIONS
944	SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection. PLoS ONE, 2022, 17, e0266701.	1.1	11
945	Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. Clinical Chemistry and Laboratory Medicine, 2022, 60, e153-e156.	1.4	7
946	Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.. Acta Biomedica, 2022, 93, e2022179.	0.2	9
947	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. Acta Biomedica, 2022, 93, e2022018.	0.2	0
948	SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses, 2022, 14, 653.	1.5	39
949	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. Science Translational Medicine, 2021, , eabj6824.	5.8	11
950	Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	3
951	Rapid Genotyping of Sars-Cov-2 Variants with a Duplex-Targeting Lateral Flow Strip by Crispr-Cas 12a/13a in Pam Independent Manner. SSRN Electronic Journal, 0, , .	0.4	0
952	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Computational and Structural Biotechnology Journal, 2022, 20, 2042-2056.	1.9	8
953	Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies. Computational and Structural Biotechnology Journal, 2022, 20, 2212-2222.	1.9	4
954	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
955	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
956	Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virology Journal, 2022, 19, 76.	1.4	61
957	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. Pathogens, 2022, 11, 516.	1.2	10
958	Variant-specific vaccination induces systems immune responses and potent inÂvivo protection against SARS-CoV-2. Cell Reports Medicine, 2022, 3, 100634.	3.3	10
959	A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy. International Journal of Infectious Diseases, 2022, 121, 85-88.	1.5	4
960	Study of correlation properties of GB-speckles generated for the SARSâ€CoV-2 gene "S" for characterization of differences between Delta and other variants. , 2022, , .		0
961	Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil. BioTech, 2022, 11, 12.	1.3	23

#	ARTICLE	IF	CITATIONS
963	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
964	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. <i>Vaccines</i> , 2022, 10, 712.	2.1	4
965	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022, 10, 857.	1.6	8
966	SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant. <i>Viruses</i> , 2022, 14, 919.	1.5	44
967	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. <i>Molecular Therapy</i> , 2022, 30, 2984-2997.	3.7	17
969	Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. <i>Frontiers in Immunology</i> , 2022, 13, 869990.	2.2	40
970	Optimizing antiviral therapy for COVID-19 with learned pathogenic model. <i>Scientific Reports</i> , 2022, 12, 6873.	1.6	8
971	Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. <i>Infection</i> , 2023, 51, 261-263.	2.3	8
972	Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective. <i>Current Vascular Pharmacology</i> , 2022, 20, 333-340.	0.8	1
973	Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	16
974	Amplifying Lateral Flow Assay Signals for Rapid Detection of COVID-19 Specific Antibodies. <i>Global Challenges</i> , 2022, 6, .	1.8	6
975	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	1.2	3
976	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
977	Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166432.	1.8	8
978	Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1024.	1.5	2
979	Fusion of Modulation Spectral and Spectral Features with Symptom Metadata for Improved Speech-Based Covid-19 Detection. , 2022, , .		4
980	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	24
981	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12

#	ARTICLE	IF	CITATIONS
982	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
983	Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. <i>Molecular Diversity</i> , 2023, 27, 463-475.	2.1	25
984	The role of children in household transmission of COVID-19: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 122, 266-275.	1.5	44
985	Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. <i>Biomedicines</i> , 2022, 10, 1067.	1.4	7
986	Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain. <i>Journal of Molecular Biology</i> , 2022, 434, 167622.	2.0	3
987	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
988	Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 841009.	2.2	0
989	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	3.3	27
990	Covid-19 vaccine immunogenicity in people living with HIV-1. <i>Vaccine</i> , 2022, 40, 3633-3637.	1.7	47
991	Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll-like receptors dictates pathophysiology of COVID-19 disease. <i>Journal of Medical Virology</i> , 2022, 94, 4088-4096.	2.5	15
992	Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029.		26
993	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
994	Frontliners on the Move: A Quantitative Analysis of the Prevalence of COVID-19 Reinfection Among Healthcare Workers. <i>Cureus</i> , 2022, , .	0.2	0
995	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. <i>Science Immunology</i> , 2022, 7, eabp8328.	5.6	40
996	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
997	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
998	Illness Characteristics of COVID-19 in Children Infected with the SARS-CoV-2 Delta Variant. <i>Children</i> , 2022, 9, 652.	0.6	28
999	SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity. <i>Journal of Chemical Information and Modeling</i> , 2022, , .	2.5	5

#	ARTICLE	IF	CITATIONS
1000	Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. <i>Npj Vaccines</i> , 2022, 7, 50.	2.9	14
1001	Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic. <i>PLOS Global Public Health</i> , 2022, 2, e0000412.	0.5	0
1002	A Review of Different Vaccines and Strategies to Combat COVID-19. <i>Vaccines</i> , 2022, 10, 737.	2.1	8
1003	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	3
1004	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
1005	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. <i>Vaccines</i> , 2022, 10, 755.	2.1	13
1006	In-silico study for the screening and preparation of ionic liquid-AVDs conjugate to combat COVID-19 surge. <i>Journal of Molecular Liquids</i> , 2022, 359, 119277.	2.3	5
1007	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
1008	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
1009	Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. <i>International Journal of Medical Sciences</i> , 2022, 19, 834-841.	1.1	4
1010	Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	13
1011	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. <i>Cell Reports Medicine</i> , 2022, 3, 100651.	3.3	24
1012	Genomics of postvaccination SARS-CoV-2 infections during the Delta dominated second wave of COVID-19 pandemic, from Mumbai Metropolitan Region (MMR), India. <i>Journal of Medical Virology</i> , 2022, 94, 4206-4215.	2.5	8
1013	Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	6
1014	Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. <i>Virology</i> , 2022, 572, 64-71.	1.1	12
1015	Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. <i>Cell Reports</i> , 2022, 39, 110905.	2.9	5
1016	Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein. , 2022, 1, .		36
1017	Predicting the Disease Severity of Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 111-139.	0.8	0

#	ARTICLE	IF	CITATIONS
1018	Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. <i>Nature Communications</i> , 2022, 13, 2766.	5.8	20
1019	Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift. <i>MAbs</i> , 2022, 14, 2076775.	2.6	5
1020	Association of PTSD with Longitudinal COVID-19 Burden in a Mixed-Serostatus Cohort of Men and Women: Weathering the Storm. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	0
1021	Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020. <i>MSphere</i> , 2022, 7, e0084121.	1.3	6
1022	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COMMUNITY Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345.	0.8	2
1023	Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. <i>PLoS ONE</i> , 2022, 17, e0268797.	1.1	13
1024	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
1025	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
1028	Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. <i>Vaccines</i> , 2022, 10, 830.	2.1	5
1030	Receptor binding domain proteins of SARS-CoV-2 variants produced in <i>Nicotiana benthamiana</i> elicit neutralizing antibodies against variants of concern. <i>Journal of Medical Virology</i> , 2022, 94, 4265-4276.	2.5	10
1032	A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. <i>Journal of Medical Virology</i> , 2022, 94, 4287-4293.	2.5	13
1033	A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
1034	Automated amplification-free digital RNA detection platform for rapid and sensitive SARS-CoV-2 diagnosis. <i>Communications Biology</i> , 2022, 5, .	2.0	28
1036	Detecting Potentially Adaptive Mutations from the Parallel and Fixed Patterns in SARS-CoV-2 Evolution. <i>Viruses</i> , 2022, 14, 1087.	1.5	4
1037	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
1039	Characterizing the Severity of SARS-CoV-2 Variants at a Single Pediatric Center. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	2
1040	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
1041	Lebanese SARS-CoV-2 genomics: 24 months of the pandemic. <i>Virus Research</i> , 2022, 317, 198824.	1.1	2

#	ARTICLE	IF	CITATIONS
1042	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. SSRN Electronic Journal, 0, , .	0.4	0
1044	Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by 3 Doses of BBIBP-CorV Vaccination During One Year. SSRN Electronic Journal, 0, , .	0.4	0
1045	Current molecular diagnostics assays for SARS-CoV-2 and emerging variants. Methods in Microbiology, 2022, , 83-121.	0.4	2
1046	Environmental Effects of the Disposable Surgical Masks for Preventing COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
1047	Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. Nature Biomedical Engineering, 2022, 6, 932-943.	11.6	76
1048	System analysis of the fast global coronavirus disease 2019 (COVID-19) spread. Can we avoid future pandemics under global climate change?. Communicative and Integrative Biology, 2022, 15, 150-157.	0.6	2
1049	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell, 2022, 40, 738-753.e5.	7.7	19
1051	Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-CoV-2 in mixed variety of vaccine background. Saudi Journal of Biological Sciences, 2022, 29, 103329.	1.8	10
1052	Dietary guidelines to boost immunity during pre and post covid-19 conditions. International Journal of Food Properties, 2022, 25, 1246-1265.	1.3	1
1053	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. IScience, 2022, 25, 104457.	1.9	8
1054	Characterization and Outcomes of SARS-CoV-2 Infection in Overweight and Obese Patients: A Dynamic Comparison of COVID-19 Pandemic Waves. Journal of Clinical Medicine, 2022, 11, 2916.	1.0	12
1055	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19
1057	Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. IScience, 2022, 25, 104431.	1.9	3
1058	Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer Journal, 2022, 12, .	2.8	23
1059	Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron. Virology Journal, 2022, 19, .	1.4	5
1060	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med, 2022, 3, 468-480.e5.	2.2	2
1061	Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19. Frontiers in Pharmacology, 0, 13, .	1.6	3
1062	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS ONE, 2022, 17, e0268767.	1.1	18

#	ARTICLE	IF	CITATIONS
1064	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
1065	Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico. <i>Viruses</i> , 2022, 14, 1165.	1.5	12
1066	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
1068	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
1069	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
1070	Two Separate Clusters of SARS-CoV-2 Delta Variant Infections in a Group of 41 Students Travelling from India: An Illustration of the Need for Rigorous Testing and Quarantine. <i>Viruses</i> , 2022, 14, 1198.	1.5	4
1071	Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice. <i>Journal of Medical Virology</i> , 0, .	2.5	4
1072	A CRISPR/Cas12a-empowered surface plasmon resonance platform for rapid and specific diagnosis of the Omicron variant of SARS-CoV-2. <i>National Science Review</i> , 2022, 9, .	4.6	56
1073	Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins—A Possible Signature of Adaptive Selection. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
1074	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
1075	Mapping of SARS-CoV-2 spike protein evolution during the first and second waves of COVID-19 infections in India. <i>Future Virology</i> , 2022, 17, 557-575.	0.9	2
1076	Covid-19, an unfinished story. <i>Presse Medicale</i> , 2022, 51, 104131.	0.8	8
1077	Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2022, 17, 463-489.	0.9	6
1079	SARS-CoV-2 Delta variant isolates from vaccinated individuals. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
1080	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	5
1081	Airborne transmission of the Delta variant of SARS-CoV-2 in an auditorium. <i>Building and Environment</i> , 2022, 219, 109212.	3.0	7
1082	Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1083	Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak. <i>Infection and Chemotherapy</i> , 2022, 54, 258.	1.0	2

#	ARTICLE	IF	CITATIONS
1084	Biological Determinants of Emergence of SARS-CoV-2 Variants. , 0, , .		0
1085	Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021â€“November 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e469-e476.	2.9	9
1086	Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. <i>Viruses</i> , 2022, 14, 1315.	1.5	0
1087	Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020â€“2021. <i>Viruses</i> , 2022, 14, 1318.	1.5	3
1088	Materialsâ€“based vaccines for infectious diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, .	3.3	4
1089	Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?. <i>Vacunas</i> , 2022, 23, S121-S122.	1.1	0
1090	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1092	Divulging Incipient SARS-CoV-2 Delta (B.1.617.2) Variant: Possible Interference with Global Scenario. <i>Infectious Disorders - Drug Targets</i> , 2023, 23, .	0.4	1
1093	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
1094	Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1095	Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. <i>Pathogens</i> , 2022, 11, 655.	1.2	5
1096	Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. <i>Trials</i> , 2022, 23, .	0.7	0
1097	Comparison among plaque assay, tissue culture infectious dose (TCID) and real-time RT-PCR for SARS-CoV-2 variants quantification. <i>Iranian Journal of Microbiology</i> , 0, , .	0.8	3
1098	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.	1.5	2
1099	Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6830.	1.8	5
1100	Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2022, , 100678.	3.3	10
1102	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1104	SARS-CoV-2 antibody prevalence in a pediatric cohort of unvaccinated children in MÃ©rida, YucatÃ¡n, MÃ©xico. <i>PLOS Global Public Health</i> , 2022, 2, e0000354.	0.5	0

#	ARTICLE	IF	CITATIONS
1105	Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2022, 2022, 1-11.	0.6	5
1106	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
1107	Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	20
1108	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
1109	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
1110	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2022, 7, 974-985.	5.9	30
1111	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1112	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
1113	Drivers of adaptive evolution during chronic SARS-CoV-2 infections. <i>Nature Medicine</i> , 2022, 28, 1501-1508.	15.2	81
1114	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. <i>Science Immunology</i> , 2022, 7, .	5.6	89
1115	Exploring the risk factors of COVID-19 Delta variant in the United States based on Bayesian spatio-temporal analysis. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	3
1116	Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield™) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. <i>Vaccines</i> , 2022, 10, 970.	2.1	6
1117	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1326.	1.5	4
1118	Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103541.	1.4	7
1119	Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	1
1120	High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2. <i>Aids</i> , 2022, 36, 1545-1552.	1.0	10
1121	RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. <i>Vaccine</i> , 2022, 40, 4522-4530.	1.7	6
1122	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4

#	ARTICLE	IF	CITATIONS
1123	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). <i>Journal of Clinical Virology</i> , 2022, 154, 105218.	1.6	12
1124	Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein. <i>MBio</i> , 2022, 13, .	1.8	23
1125	Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. <i>Journal of Personalized Medicine</i> , 2022, 12, 995.	1.1	9
1126	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
1127	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1128	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	14
1129	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15
1130	Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. <i>Med</i> , 2022, , .	2.2	2
1131	Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
1132	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. <i>Vaccine</i> , 2022, 40, 4220-4230.	1.7	27
1133	Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion. <i>Virology</i> , 2022, 573, 84-95.	1.1	1
1134	The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2022, 119, 106822.	0.8	10
1135	Accurate identification of SARS-CoV-2 variant delta using graphene/CRISPR-dCas9 electrochemical biosensor. <i>Talanta</i> , 2022, 249, 123687.	2.9	13
1136	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , .	1.0	0
1137	Multiplex Technologies in COVID-19 Research, Diagnostics, and Prognostics: Battling the Pandemic. <i>Methods in Molecular Biology</i> , 2022, , 3-20.	0.4	2
1139	Alkaloids and Alkaloid-Like Compounds are Potential Scaffolds of Antiviral Agents against SARS-CoV-2 (COVID-19) Virus. <i>Heterocycles</i> , 2022, 105, 115.	0.4	2
1141	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
1142	EFFICACY OF MONOCLONAL ANTIBODIES ASSOCIATION IN PRESENCE OF TWO SARS-COV-2 DOMINANT VARIANT OF CONCERN. COMPARATIVE STUDY VERSUS MONOTHERAPY AGAINST A SINGLE VARIANT: A REAL EXPERIENCE IN UMBRIA, ITALY.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022050.	0.5	0

#	ARTICLE	IF	CITATIONS
1143	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
1144	The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. <i>Current Issues in Molecular Biology</i> , 2022, 44, 2842-2855.	1.0	1
1145	IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. <i>Science Immunology</i> , 2022, 7, .	5.6	8
1146	Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. <i>Journal of Infectious Diseases</i> , 2022, 226, 1407-1411.	1.9	6
1147	Development and validation of a PCR-free nucleic acid testing method for RNA viruses based on linear molecular beacon probes. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	1
1148	Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1149	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6064-6073.	2.1	14
1150	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1151	COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	39
1152	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
1153	Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1154	Third booster vaccination and stopping the Omicron, a new variant of concern. <i>Vacunas</i> , 2022, 23, S103-S110.	1.1	5
1155	A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	29
1156	Raman Fingerprints of the SARS-CoV-2 Delta Variant and Mechanisms of Its Instantaneous Inactivation by Silicon Nitride Bioceramics. <i>ACS Infectious Diseases</i> , 2022, 8, 1563-1581.	1.8	7
1158	Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. <i>Immunity</i> , 2022, 55, 1732-1746.e5.	6.6	40
1159	Immune responses to Sinopharm/BBIBP-CoV in individuals in Sri Lanka. <i>Immunology</i> , 2022, 167, 275-285.	2.0	8
1160	Inhibition of SARS-CoV-2 wild-type (Wuhan-Hu-1) and Delta (B.1.617.2) strains by marine sulfated glycans. <i>Glycobiology</i> , 0, , .	1.3	5
1161	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5

#	ARTICLE	IF	CITATIONS
1162	Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort. PLoS Computational Biology, 2022, 18, e1009834.	1.5	1
1163	Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs. Diagnostic Microbiology and Infectious Disease, 2022, 104, 115758.	0.8	7
1164	SARS-CoV-2 reinfections in a US university setting, Fall 2020 to Spring 2021. BMC Infectious Diseases, 2022, 22, .	1.3	5
1165	Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. Current Issues in Molecular Biology, 2022, 44, 3018-3029.	1.0	6
1166	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. Proteomics, 0, , 2200118.	1.3	3
1168	Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2022, 20, 2558-2566.e5.	2.4	28
1169	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host and Microbe, 2022, 30, 1231-1241.e6.	5.1	55
1170	Monoclonal antibody therapies against SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, e311-e326.	4.6	114
1171	Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada. Frontiers in Public Health, 0, 10, .	1.3	3
1172	Determining the International Spread of B.1.1.523 SARS-CoV-2 Lineage with a Set of Mutations Highly Associated with Reduced Immune Neutralization. Microorganisms, 2022, 10, 1356.	1.6	1
1173	Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Molecular Medicine, 2022, 14, .	3.3	35
1174	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5707-5727.	2.0	7
1175	Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage. Frontiers in Pharmacology, 0, 13, .	1.6	0
1176	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. Journal of Virology, 2022, 96, .	1.5	11
1178	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. Journal of Infectious Diseases, 2023, 227, 1143-1152.	1.9	16
1179	The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses. Cell Reports, 2022, 40, 111138.	2.9	13
1180	Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis. Liver International, 2023, 43, 393-400.	1.9	11
1181	SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. IScience, 2022, 25, 104759.	1.9	11

#	ARTICLE	IF	CITATIONS
1182	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 758-766.	1.5	15
1183	COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
1184	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. <i>Nature Communications</i> , 2022, 13, .	5.8	43
1185	The global succinylation of SARS-CoV-2-infected host cells reveals drug targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
1186	Social contributors for the rise of COVID-19 infections in South Asia: A large cross-sectional survey. <i>Annals of Medicine and Surgery</i> , 2022, , 104212.	0.5	1
1188	Epidemiologic Profile of Severe Acute Respiratory Infection in Brazil During the COVID-19 Pandemic: An Epidemiological Study. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	13
1189	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	3
1190	A Visual Assay of a Loop-Mediated Isothermal Amplification Based Vertical Immunoassay for SARS-CoV-2 RNA Detection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
1191	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature</i> , 2022, 608, 603-608.	13.7	541
1192	Simulation of group testing scenarios can boost COVID-19 screening power. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1193	Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wildtype and its variants in one assay: Rational tool for the assessment of protective immunity.. <i>Journal of Medical Virology</i> , 0, , .	2.5	6
1194	Pharmacokinetic Study of Coadministration with Cefuroxime Sodium for Injection Influencing ReDuNing Injection-Derived Seven Phytochemicals and Nine Metabolites in Rats. <i>Journal of Analytical Methods in Chemistry</i> , 2022, 2022, 1-17.	0.7	3
1195	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>IScience</i> , 2022, 25, 104705.	1.9	8
1196	Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy. <i>Pathogens</i> , 2022, 11, 823.	1.2	14
1199	A comparison of high-throughput SARS-CoV-2 sequencing methods from nasopharyngeal samples. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1200	The trispesific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. <i>Nature Biotechnology</i> , 2022, 40, 1845-1854.	9.4	25
1201	Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
1202	Why does COVID-19 continue to spread despite mass vaccination?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2

#	ARTICLE	IF	CITATIONS
1203	A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1204	SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	8
1205	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. <i>Science Immunology</i> , 2022, 7, .	5.6	170
1206	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11
1207	Real-world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 0, , .	1.3	1
1208	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	1.8	5
1209	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1210	Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1255-1268.e5.	5.1	45
1211	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1212	Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4015-4024.	1.9	14
1213	BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1214	covSampler: A subsampling method with balanced genetic diversity for large-scale SARS-CoV-2 genome data sets. <i>Virus Evolution</i> , 2022, 8, .	2.2	3
1215	Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1â€“August 20, 2021): a retrospective observational monocentric study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
1216	Peimine inhibits variants of <scp>SARSâ€™CoV</scp> â€™ cell entry via blocking the interaction between viral spike protein and <scp>ACE2</scp>. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	8
1217	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. <i>Nature Communications</i> , 2022, 13, .	5.8	24
1218	Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2022, 227, 23-34.	1.9	21
1219	Self-Reported Olfactory and Gustatory Dysfunctions in Hospitalized Patients Infected with SARS-CoV-2 Delta Variant. <i>Ear, Nose and Throat Journal</i> , 0, , 014556132211169.	0.4	0
1220	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10

#	ARTICLE	IF	CITATIONS
1223	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1224	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. <i>Virus Evolution</i> , 2022, 8, .	2.2	10
1226	Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
1227	Missense mutations in spike protein of SARS-CoV-2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	6
1228	COVID-19 and vaccination: myths vs science. <i>Expert Review of Vaccines</i> , 2022, 21, 1603-1620.	2.0	23
1229	A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
1230	Genomic epidemiology of the first two waves of SARS-CoV-2 in Canada. <i>ELife</i> , 0, 11, .	2.8	21
1232	Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey. <i>MBio</i> , 2022, 13, .	1.8	6
1233	Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	33
1234	Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
1237	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. <i>Science</i> , 2022, 25, 104914.	1.9	5
1238	Non-pharmacological interventions of travel restrictions and cancelation of public events had a major reductive mortality affect during pre-vaccination coronavirus disease 2019 period. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1239	Homeopathic Medicines in Second Wave of COVID-19: Prognostic Factor Research. <i>Homeopathy</i> , 2023, 112, 012-021.	0.5	4
1240	Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1241	Depression, Anxiety and Quality of Life among Online Responders in Poland: A Cross-Sectional Study Covering Four Waves of the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9934.	1.2	3
1242	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. <i>MSphere</i> , 2022, 7, .	1.3	8
1243	Differential Infectivity of Original and Delta Variants of SARS-CoV-2 in Children Compared to Adults. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
1244	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Emerging Microbes and Infections</i> , 2022, 11, 2315-2325.	3.0	3

#	ARTICLE	IF	CITATIONS
1245	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
1246	Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021â€“2022: A Naturalistic Case-Control Study in Sweden. <i>Vaccines</i> , 2022, 10, 1273.	2.1	1
1247	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. <i>Human Immunology</i> , 2022, 83, 755-767.	1.2	10
1248	<scp>COVID</scp>â€“19 vaccine humoral response in frequent platelet donors with plateletpheresisâ€“associated lymphopenia. <i>Transfusion</i> , 2022, 62, 1779-1790.	0.8	4
1249	Cross-Border Transmissions of the Delta Substrain AY.29 During Tokyo Olympic and Paralympic Games. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
1250	IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	15
1251	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3
1252	Impaired immunity and high attack rates caused by SARSâ€“CoVâ€“2 variants among vaccinated longâ€“term care facility residents. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
1254	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
1255	Surface Inactivation of Highly Mutated SARS-CoV-2 Variants of Concern: Alpha, Delta, and Omicron. <i>Biomacromolecules</i> , 2022, 23, 3960-3967.	2.6	1
1257	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. <i>Scientific Reports</i> , 2022, 12, .	1.6	26
1258	Development and Validation of an In-House Real-Time Reverse-Transcriptase Polymerase Chain Reaction Assay for SARS-CoV-2 Omicron Lineage Subtyping between BA.1 and BA.2. <i>Viruses</i> , 2022, 14, 1760.	1.5	0
1259	Molnupiravir for treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
1260	A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. <i>Cell Reports</i> , 2022, 40, 111335.	2.9	2
1261	Design and Immunoinformatic Assessment of Candidate Multivalent mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3
1262	Single-Nanoparticle-Based Digital SERS Sensing Platform for the Accurate Quantitative Detection of SARS-CoV-2. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 38459-38470.	4.0	13
1263	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1264	The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. <i>Emerging Microbes and Infections</i> , 2022, 11, 2093-2101.	3.0	5

#	ARTICLE	IF	CITATIONS
1265	Comparison of the unbinding process of RBD-ACE2 complex between SARS-CoV-2 variants (Delta, delta) Tj ETQq0 0,9 rgBT /Q Overlock 10		
1266	Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	6
1268	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. <i>Med</i> , 2022, 3, 760-773.e5.	2.2	13
1269	Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. <i>Vaccines</i> , 2022, 10, 1251.	2.1	10
1270	Attitudes towards COVID-19 Booster Vaccines, Vaccine Preferences, Child Immunization, and Recent Issues in Vaccination among University Students in Jordan. <i>Vaccines</i> , 2022, 10, 1258.	2.1	3
1271	Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1272	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
1273	Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis. <i>Indian Journal of Medical Microbiology</i> , 2022, 40, 585-587.	0.3	3
1275	Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape. <i>Folia Microbiologica</i> , 2023, 68, 17-28.	1.1	16
1276	Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. <i>Structure</i> , 2022, 30, 1432-1442.e4.	1.6	18
1277	ELF5 is a potential respiratory epithelial cell-specific risk gene for severe COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1278	Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya. <i>Communications Medicine</i> , 2022, 2, .	1.9	4
1279	Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. <i>EBioMedicine</i> , 2022, 83, 104217.	2.7	44
1280	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. <i>EBioMedicine</i> , 2022, 83, 104196.	2.7	26
1281	Rapid SARS-CoV-2 disinfection on distant surfaces with UV-C: The inactivation is affected by the type of material. <i>Journal of Photochemistry and Photobiology</i> , 2022, 11, 100138.	1.1	4
1282	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 980-997.	3.6	28
1283	Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants. <i>Journal of Clinical Virology</i> , 2022, 155, 105268.	1.6	2
1284	Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant. <i>Journal of Clinical Virology</i> , 2022, 155, 105253.	1.6	6

#	ARTICLE	IF	CITATIONS
1285	Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. <i>Computers in Biology and Medicine</i> , 2022, 149, 105969.	3.9	7
1286	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
1287	Exhaled breath SARS-CoV-2 shedding patterns across variants of concern. <i>International Journal of Infectious Diseases</i> , 2022, 123, 25-33.	1.5	4
1288	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
1289	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
1290	From Alpha to Omicron BA.2: New digital RT-PCR approach and challenges for SARS-CoV-2 VOC monitoring and normalization of variant dynamics in wastewater. <i>Science of the Total Environment</i> , 2022, 848, 157740.	3.9	13
1291	A Deterministic-Statistical Hybrid Forecast Model: The Future of the COVID-19 Contagious Process in Several Regions of Mexico. <i>Systems</i> , 2022, 10, 138.	1.2	1
1292	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
1293	In vitro antiviral effect of silver nanoparticles against SARS-CoV-2. <i>Iatreia</i> , 0, , .	0.1	0
1294	Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1502.	2.1	1
1295	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
1296	Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. <i>Respiratory Medicine</i> , 2022, 202, 106986.	1.3	6
1297	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
1298	State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic. <i>OpenNano</i> , 2022, 8, 100078.	1.8	11
1299	High-performance multifunctional electrospun fibrous air filter for personal protection: A review. <i>Separation and Purification Technology</i> , 2022, 302, 122175.	3.9	42
1300	Omicron variant: Current insights and future directions. <i>Microbiological Research</i> , 2022, 265, 127204.	2.5	32
1301	Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic. <i>Science of the Total Environment</i> , 2022, 853, 158458.	3.9	19
1302	Wastewater to clinical case (WC) ratio of COVID-19 identifies insufficient clinical testing, onset of new variants of concern and population immunity in urban communities. <i>Science of the Total Environment</i> , 2022, 853, 158547.	3.9	19

#	ARTICLE	IF	CITATIONS
1303	Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, 6, 100079.	0.6	4
1304	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
1305	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies. <i>Communications in Information and Systems</i> , 2022, 22, 339-361.	0.3	2
1306	A kinetic model considering the decline of antibody level and simulation about vaccination effect of COVID-19. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 12558-12580.	1.0	0
1307	SARS-CoV-2 Infection of Lung Organoids Reveals Conserved Use of Tetraspanin-8 by Ancestral-, Delta-, and Omicron- Variants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1308	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791.	2.6	5
1309	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1310	Biophysical and structural characterizations of the effects of mutations on the structureâ€“activity relationships of SARS-CoV-2 spike protein. <i>Methods in Enzymology</i> , 2022, , 299-321.	0.4	2
1311	The BNT162b2 mRNA SARS-CoV-2 Vaccine Induces Transient Afucosylated IgG1 in Naive But Not in Antigen-Experienced Vaccinees. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1312	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
1313	SARS-COV-2 and Other mRNA Vaccines. <i>RNA Technologies</i> , 2022, , 113-138.	0.2	0
1314	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. <i>Health Evaluation and Promotion</i> , 2022, 49, 462-469.	0.0	0
1315	Human Claudin-Derived Peptides Block the Membrane Fusion Process of Zika Virus and Are Broad Flavivirus Inhibitors. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1316	SARS-CoV-2 Infections in Vaccinated and Unvaccinated Populations in Camp Lemonnier, Djibouti, from April 2020 to January 2022. <i>Viruses</i> , 2022, 14, 1918.	1.5	0
1317	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. <i>Life</i> , 2022, 12, 1318.	1.1	3
1318	Third Early â€œBoosterâ€“Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. <i>Viruses</i> , 2022, 14, 1928.	1.5	5
1319	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
1321	Predicting SARS-CoV-2 Variant Spread in a Completely Seropositive Population Using Semi-Quantitative Antibody Measurements in Blood Donors. <i>Vaccines</i> , 2022, 10, 1437.	2.1	5

#	ARTICLE	IF	CITATIONS
1322	The role of B cells in COVID-19 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
1323	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders. <i>Pharmaceuticals</i> , 2022, 15, 1084.	1.7	5
1324	Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010563.	1.5	4
1325	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
1327	A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection. <i>Journal of Virology</i> , 2022, 96, .	1.5	10
1328	A replication-competent smallpox vaccine LC16m8 ¹ -based COVID-19 vaccine. <i>Emerging Microbes and Infections</i> , 2022, 11, 2359-2370.	3.0	5
1329	Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants. <i>Wiener Klinische Wochenschrift</i> , 0, , .	1.0	0
1330	New insights into human immune memory from SARS-CoV-2 infection and vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 0, , .	2.7	5
1331	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1332	Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis. <i>Biosensors</i> , 2022, 12, 728.	2.3	13
1333	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1334	Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
1335	A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination. <i>Viruses</i> , 2022, 14, 2118.	1.5	1
1336	Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents. <i>Vaccines</i> , 2022, 10, 1474.	2.1	2
1337	Tracing the trajectories of SARS-CoV-2 variants of concern between December 2020 and September 2021 in the Canary Islands (Spain). <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
1338	Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor. <i>Viruses</i> , 2022, 14, 2075.	1.5	9
1339	Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
1340	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12

#	ARTICLE	IF	CITATIONS
1341	GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2â€R671 diâ€Rmethylation. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	9
1342	A counterintuitive antibody cocktail disrupts coxsackievirus. <i>Cell Host and Microbe</i> , 2022, 30, 1194-1195.	5.1	1
1343	SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?. <i>Genomics</i> , 2022, 114, 110466.	1.3	18
1344	A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1345	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1346	Anti-SARS-CoV-2 and anticoagulant properties of <i>Pentacta pygmaea</i> fucosylated chondroitin sulfate depend on high molecular weight structures. <i>Glycobiology</i> , 2023, 33, 75-85.	1.3	10
1347	Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics. <i>Viruses</i> , 2022, 14, 2017.	1.5	3
1348	Pathogen evolution during vaccination campaigns. <i>PLoS Biology</i> , 2022, 20, e3001804.	2.6	11
1349	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
1350	Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-Î² Conjugated Exosomes. <i>Pharmaceutical Research</i> , 0, , .	1.7	2
1351	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11325.	1.8	6
1352	A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
1354	A Bioinformatics Tool for Predicting Future COVID-19 Waves Based on a Retrospective Analysis of the Second Wave in India: Model Development Study. <i>JMIR Bioinformatics and Biotechnology</i> , 2022, 3, e36860.	0.4	4
1355	Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2022, 8, .	4.7	14
1356	Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1Î² associate with COVID-19 fatal outcome: A cross-sectional analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1357	Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. <i>Communications Biology</i> , 2022, 5, .	2.0	13
1358	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. <i>Viruses</i> , 2022, 14, 1966.	1.5	6
1359	A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	5

#	ARTICLE	IF	CITATIONS
1360	Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations. <i>Immunology Letters</i> , 2022, 249, 23-32.	1.1	4
1361	A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques. <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	3
1362	CHARMMâ€œGUI <i>Enhanced Sampler</i> for <scp>various collective variables</scp> and <scp>enhanced sampling methods</scp>. <i>Protein Science</i> , 2022, 31, .	3.1	9
1363	Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. <i>Vaccines</i> , 2022, 10, 1548.	2.1	25
1365	Localized delivery of nanomedicine and antibodies for combating COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1828-1846.	5.7	5
1366	Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBPâ€œCoV vaccination during one year. <i>Proteomics</i> , 0, , 2200306.	1.3	2
1367	Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors. <i>Viral Immunology</i> , 2022, 35, 545-552.	0.6	4
1368	The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs. <i>Molecular Therapy</i> , 2022, 30, 3101-3105.	3.7	4
1369	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. <i>Science</i> , 2022, 378, .	6.0	64
1370	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. <i>Med</i> , 2022, 3, 838-847.e3.	2.2	26
1371	Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1372	Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1373	SARS-CoV-2 Omicron variant emerged under immune selection. <i>Nature Microbiology</i> , 2022, 7, 1756-1761.	5.9	21
1375	IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, .	5.8	5
1377	Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1378	Importancia de la vigilancia genÃ³mica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1379	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
1380	Molecular Docking of Active Compounds from Traditional Medicinal Plants as ACE-2 protein (1R4L) inhibitor in searching for COVID-19 drug. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 4235-4240.	0.2	5

#	ARTICLE	IF	CITATIONS
1381	Healthcare-Associated COVID-19 across Five Pandemic Waves: Prediction Models and Genomic Analyses. <i>Viruses</i> , 2022, 14, 2292.	1.5	1
1382	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. <i>Cell Reports</i> , 2022, 41, 111496.	2.9	20
1383	Genomic Analysis of SARS-CoV-2 Alpha, Beta and Delta Variants of Concern Uncovers Signatures of Neutral and Non-Neutral Evolution. <i>Viruses</i> , 2022, 14, 2375.	1.5	4
1384	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
1385	De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. <i>Science Advances</i> , 2022, 8, .	4.7	9
1386	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
1388	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
1390	Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review. <i>Infection and Drug Resistance</i> , 0, Volume 15, 6317-6330.	1.1	11
1391	The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview. <i>Journal of Molecular Pathology</i> , 2022, 3, 201-218.	0.5	13
1392	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2
1393	Estimation of R0 for the spread of SARS-CoV-2 in Germany from excess mortality. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1394	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. <i>Microorganisms</i> , 2022, 10, 1999.	1.6	4
1395	Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: A retrospective observational study from a cancer hospital in eastern India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	0
1396	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1397	Genetic, Structural, Physicochemical, and Molecular Epidemiological Landscape of Three New Mutations Found in the Spike (S) Protein of Highly Transmissible Sri Lankan Delta Variant Sub-lineage AY.28: A222V, A701S, and A1078S. <i>Journal of Environmental and Public Health</i> , 2022, 2022, 1-8.	0.4	0
1398	Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. <i>ACS Nano</i> , 2022, 16, 16757-16775.	7.3	11
1400	Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study. <i>American Journal of Health-System Pharmacy</i> , 2023, 80, 130-136.	0.5	2
1401	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. <i>Nature Reviews Microbiology</i> , 2023, 21, 112-124.	13.6	128

#	ARTICLE	IF	CITATIONS
1402	Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach. <i>Life</i> , 2022, 12, 1715.	1.1	2
1403	Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13220.	1.8	5
1405	Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12997.	1.2	3
1407	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
1408	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1409	Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Dosesâ€™ Vaccinated Solid Organ Transplant Recipients. <i>Viruses</i> , 2022, 14, 2299.	1.5	7
1410	A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1653.	2.1	1
1411	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.	2.1	7
1412	SARSâ€™CoVâ€™2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
1413	Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 465-476.	2.3	6
1414	Cartography of SARSâ€™CoVâ€™2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1415	Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1416	An ultrasensitive and rapid â€™sample-to-answerâ€™-microsystem for on-site monitoring of SARS-CoV-2 in aerosols using â€™in situâ€™-tetra-primer recombinase polymerase amplification. <i>Biosensors and Bioelectronics</i> , 2023, 219, 114816.	5.3	6
1417	Household secondary attack rate in SARS-CoV-2 infection during the second wave of the COVID-19 pandemic in South India. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6268.	0.3	0
1418	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
1419	Dual Inhibitors of Main Protease (M ^{Pro}) and Cathepsin L as Potent Antivirals against SARS-CoV2. <i>Journal of the American Chemical Society</i> , 2022, 144, 21035-21045.	6.6	20
1420	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14057.	1.8	4
1421	A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13716.	1.8	3

#	ARTICLE	IF	CITATIONS
1423	COVID-19 pandemic to endemic. <i>International Journal of Clinical Virology</i> , 2022, 6, 043-049.	0.1	0
1424	Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1425	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	1
1426	Survival analysis of patients with COVID-19 admitted at six hospitals in Uganda in 2021: a cohort study. <i>Archives of Public Health</i> , 2022, 80, .	1.0	2
1427	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	2
1429	The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance. <i>Journal of Virology</i> , 2022, 96, .	1.5	21
1432	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
1433	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. <i>Vaccines</i> , 2022, 10, 1926.	2.1	29
1434	A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort. <i>BMC Immunology</i> , 2022, 23, .	0.9	4
1435	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. <i>PLoS Biology</i> , 2022, 20, e3001871.	2.6	11
1436	COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients. <i>Vaccines</i> , 2022, 10, 1911.	2.1	1
1437	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. <i>Nature</i> , 2023, 613, 558-564.	13.7	159
1438	SARS-CoV-2 detection by targeting four loci of viral genome using graphene oxide and gold nanoparticle DNA biosensor. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1439	Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	0
1440	A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1442	Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases. <i>Experimental Biology and Medicine</i> , 2022, 247, 1923-1936.	1.1	1
1443	Cytokine Profiling in Different SARS-CoV-2 Genetic Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14146.	1.8	10
1444	The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees. <i>EBioMedicine</i> , 2023, 87, 104408.	2.7	11

#	ARTICLE	IF	CITATIONS
1445	Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster. <i>Antiviral Research</i> , 2023, 209, 105507.	1.9	3
1446	Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital. <i>Journal of Infection and Public Health</i> , 2023, 16, 171-181.	1.9	2
1447	Preparation, characterization, and air filtration property of electrospun bimodal fibrous membrane based on low conductivity blended polymers solution. <i>Materials Today Communications</i> , 2023, 34, 105014.	0.9	7
1448	Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?. <i>Vacunas (English Edition)</i> , 2022, 23, S121-S122.	0.3	0
1449	An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1450	Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab. <i>Viruses</i> , 2022, 14, 2677.	1.5	8
1451	Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14670.	1.8	7
1452	Structural evolution of Delta lineage of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 1116-1140.	3.6	5
1453	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1454	Investigation of SARS-CoV-2 Variants and Their Effect on SARS-CoV-2 Monoclonal Antibodies, Convalescent and Vaccine Plasma by a Novel Web Tool. <i>Diagnostics</i> , 2022, 12, 2869.	1.3	1
1455	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. <i>Biomolecules</i> , 2022, 12, 1742.	1.8	6
1456	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
1457	Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. <i>International Immunology</i> , 2023, 35, 197-207.	1.8	4
1459	Plantaricin NC8 rapidly and efficiently inhibits flaviviruses and SARS-CoV-2 by disrupting their envelopes. <i>PLoS ONE</i> , 2022, 17, e0278419.	1.1	4
1460	Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 714-722.	0.8	4
1461	Exploring Geographical Topologies and Diffusion of Monkeypox Infections at the Beginning Pandemic. , 2022, , .		0
1462	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
1463	Second mRNA Vaccination of COVID-19 in a Patient Who Developed Pericarditis after the First Vaccination. <i>International Heart Journal</i> , 2022, 63, 1212-1214.	0.5	1

#	ARTICLE	IF	CITATIONS
1464	Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	3
1465	SARS-CoV-2 and animals, a long story that doesn't have to end now: What we need to learn from the emergence of the Omicron variant. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	1
1466	Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants. <i>Virology Journal</i> , 2022, 19, .	1.4	3
1468	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
1469	Complete Genomic Characterisation and Mutation Patterns of Iraqi SARS-CoV-2 Isolates. <i>Diagnostics</i> , 2023, 13, 8.	1.3	0
1470	Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia. <i>Vaccines</i> , 2022, 10, 2144.	2.1	1
1471	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
1472	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
1473	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. <i>Science Advances</i> , 2022, 8, .	4.7	9
1474	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. <i>Vaccines</i> , 2022, 10, 2110.	2.1	2
1475	Case series in Indonesia: B.1.617.2 (delta) variant of SARS-CoV-2 infection after a second dose of vaccine. <i>World Journal of Clinical Cases</i> , 0, 10, 13216-13226.	0.3	1
1477	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 212-222.	1.5	9
1480	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. <i>Nature Reviews Immunology</i> , 2023, 23, 381-396.	10.6	61
1481	Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database. <i>BMJ Open</i> , 2022, 12, e064953.	0.8	2
1482	SARS-CoV-2'İN SÖE REGELEN EVRÄ°MÄ°: PANDEMÄ°NÄ°N SONUNA NE KADAR YAKINIZ?. <i>Journal of Biotechnology and Strategic Health Research</i> , 0, .	0.8	0
1483	Emergence of a unique SARS-CoV-2 Delta sub-cluster harboring a constellation of co-appearing non-spike mutations. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1486	Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. <i>IScience</i> , 2023, 26, 105862.	1.9	8
1487	A genetically engineered, stem-cell-derived cellular vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100843.	3.3	0

#	ARTICLE	IF	CITATIONS
1488	Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. <i>Vaccines</i> , 2022, 10, 2132.	2.1	6
1489	Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster. <i>Microbes and Infection</i> , 2023, 25, 105101.	1.0	3
1490	Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA. <i>MBio</i> , 2023, 14, .	1.8	5
1492	The benefits and costs of U.S. employer COVID-19 vaccine mandates. <i>Risk Analysis</i> , 2023, 43, 2053-2068.	1.5	1
1493	Functionalized Fullerene for Inhibition of SARS-CoV-2 Variants. <i>Small</i> , 2023, 19, .	5.2	8
1494	New nickel(<i>ii</i>) Schiff base complexes as potential tools against SARS-CoV-2 Omicron target proteins: an <i>in silico</i> approach. <i>New Journal of Chemistry</i> , 2023, 47, 2350-2371.	1.4	4
1495	The "myth" of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19™ is far from reality. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1496	Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management. <i>Vaccines</i> , 2023, 11, 160.	2.1	10
1497	Genome Structure, Life Cycle, and Taxonomy of Coronaviruses and the Evolution of SARS-CoV-2. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 305-339.	0.7	3
1498	European Black Elderberry Fruit Extract Inhibits Replication of SARS-CoV-2 In Vitro. <i>Nutraceuticals</i> , 2023, 3, 91-106.	0.6	3
1499	SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1500	Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	3
1501	Boosting maternal and neonatal anti-SARS-CoV-2 humoral immunity using a third mRNA vaccine dose. <i>JCI Insight</i> , 2023, 8, .	2.3	0
1502	Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1503	Dynamics of nosocomial SARS-CoV-2 transmissions: Facing the challenge of variants of concern in a Brazilian reference hospital. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
1504	A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19). <i>Antibodies</i> , 2023, 12, 5.	1.2	15
1505	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
1506	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1

#	ARTICLE	IF	CITATIONS
1507	The rapid and highly parallel identification of antibodies with defined biological activities by SLISY. <i>Nature Communications</i> , 2023, 14, .	5.8	1
1508	On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. <i>Viruses</i> , 2023, 15, 70.	1.5	2
1509	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	19
1511	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. <i>Viruses</i> , 2023, 15, 119.	1.5	6
1512	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. <i>Medical Microbiology and Immunology</i> , 2023, 212, 103-122.	2.6	18
1513	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
1514	Biology of the SARS-CoV-2 Coronavirus. <i>Biochemistry (Moscow)</i> , 2022, 87, 1662-1678.	0.7	2
1515	In vitro infection of human ocular tissues by SARS-CoV-2 lineage A isolates. <i>BMC Ophthalmology</i> , 2022, 22, .	0.6	0
1516	Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo. <i>Virologica Sinica</i> , 2023, 38, 257-267.	1.2	2
1518	Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. <i>Viruses</i> , 2023, 15, 346.	1.5	4
1519	Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
1520	Transmission of Classical Swine Fever Virus in Cohabiting Piglets with Various Immune Statuses Following Attenuated Live Vaccine. <i>Animals</i> , 2023, 13, 368.	1.0	0
1521	Energetic and frustration analysis of SARS-CoV-2 nucleocapsid protein mutations. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-21.	2.4	0
1522	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. <i>Viral Immunology</i> , 0, , .	0.6	1
1523	Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	4
1524	Comparative admission rates and infection severity of COVID-19 among unvaccinated and vaccinated patients. <i>Journal of Investigative Medicine</i> , 2023, 71, 329-338.	0.7	1
1525	A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. <i>Nature Materials</i> , 0, , .	13.3	9
1526	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0

#	ARTICLE	IF	CITATIONS
1527	Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1528	Machine learning identifies T cell receptor repertoire signatures associated with COVID-19 severity. <i>Communications Biology</i> , 2023, 6, .	2.0	7
1529	First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCov2. <i>Lancet Microbe</i> , The, 2023, 4, e140-e148.	3.4	7
1530	A comparative study of eight serological methods shows that spike protein-based ELISAs are the most accurate tests for serodiagnosing SARS-CoV-2 infections in cats and dogs. <i>Frontiers in Veterinary Science</i> , 0, 10, .	0.9	6
1531	Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2. <i>Journal of Biological Chemistry</i> , 2023, 299, 102954.	1.6	4
1532	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. <i>Diagnostics</i> , 2023, 13, 559.	1.3	12
1533	Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). <i>BMJ Open</i> , 2023, 13, e068803.	0.8	4
1534	Scalable Inhibitors of the Nsp3-Nsp4 Coupling in SARS-CoV-2. <i>ACS Omega</i> , 2023, 8, 5349-5360.	1.6	4
1535	STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2. <i>Nano Letters</i> , 2023, 23, 2593-2600.	4.5	15
1536	The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China. <i>BMC Public Health</i> , 2023, 23, .	1.2	1
1537	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	4
1539	Adaptive Evolution of the Spike Protein in Coronaviruses. <i>Molecular Biology and Evolution</i> , 2023, 40, .	3.5	6
1540	Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1541	Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether- β -cyclodextrin content. <i>British Journal of Pharmacology</i> , 2023, 180, 2064-2084.	2.7	6
1542	The original strain of SARS-CoV-2, the Delta variant, and the Omicron variant infect microglia efficiently, in contrast to their inability to infect neurons: Analysis using 2D and 3D cultures. <i>Experimental Neurology</i> , 2023, 363, 114379.	2.0	10
1543	In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. <i>EBioMedicine</i> , 2023, 91, 104561.	2.7	14
1544	Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers. <i>Vaccine: X</i> , 2023, 14, 100288.	0.9	1
1545	The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies. <i>Heliyon</i> , 2023, 9, e14108.	1.4	1

#	ARTICLE	IF	CITATIONS
1546	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
1547	Role of vaccine in fighting the variants of COVID-19. <i>Chaos, Solitons and Fractals</i> , 2023, 168, 113159.	2.5	2
1548	SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: Implications for epidemic control. <i>PLoS ONE</i> , 2023, 18, e0280756.	1.1	0
1549	Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model. <i>IScience</i> , 2023, 26, 106092.	1.9	5
1550	Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 247-268.	2.5	1
1551	High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. <i>PLoS Pathogens</i> , 2023, 19, e1011119.	2.1	2
1552	Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant. <i>Journal of Personalized Medicine</i> , 2023, 13, 279.	1.1	3
1553	Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. <i>IScience</i> , 2023, 26, 106124.	1.9	4
1554	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	1.0	10
1555	COVID-19 therapy and vaccination: a clinical narrative review. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	10
1556	Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	15
1557	Molecular epidemiological analysis of SARS-CoV-2 genovariants in Moscow and Moscow region. <i>Voprosy Virusologii</i> , 2023, 67, 496-505.	0.1	1
1558	Genomic and phenotypic analyses suggest moderate fitness differences among Zika virus lineages. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011055.	1.3	2
1560	An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. <i>Nature Materials</i> , 2023, 22, 903-912.	13.3	13
1561	Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. <i>International Journal of Infectious Diseases</i> , 2023, 129, 188-196.	1.5	10
1562	Effect of Coronavirus Disease 2019 on Fluorine-18 fluorodeoxyglucose Uptake of Endocrine Organs. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
1563	Genomic epidemiology of SARS-CoV-2 infections in The Gambia: an analysis of routinely collected surveillance data between March, 2020, and January, 2022. <i>The Lancet Global Health</i> , 2023, 11, e414-e424.	2.9	3
1564	Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology. <i>Vaccines</i> , 2023, 11, 442.	2.1	0

#	ARTICLE	IF	CITATIONS
1565	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2)., 2023, , 1-15.		0
1566	The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. <i>Pathogens</i> , 2023, 12, 329.	1.2	3
1567	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
1569	Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1570	Computational framework to understand the clinical stages of COVID-19 and visualization of time course for various treatment strategies. <i>Biotechnology and Bioengineering</i> , 0, , .	1.7	1
1571	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
1572	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4398.	1.8	0
1573	SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants. <i>Stem Cell Reports</i> , 2023, 18, 636-653.	2.3	3
1574	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
1575	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
1576	Development of therapeutic antibodies for the treatment of infection diseases and future aspect. <i>Drug Delivery System</i> , 2022, 37, 378-387.	0.0	1
1577	Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1578	Insights into organoid-based modeling of COVID-19 pathology. <i>Virology Journal</i> , 2023, 20, .	1.4	1
1579	Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies. <i>IScience</i> , 2023, 26, 106283.	1.9	5
1580	Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan. <i>Access Microbiology</i> , 2023, 5, .	0.2	0
1581	Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase I Study. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	1
1582	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968.	1.7	17
1583	Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. <i>Antiviral Research</i> , 2023, 212, 105576.	1.9	5

#	ARTICLE	IF	CITATIONS
1584	Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals. <i>Frontiers in Virology</i> , 0, 3, .	0.7	0
1585	Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. <i>Molecules</i> , 2023, 28, 2332.	1.7	6
1586	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1587	Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras. <i>Research</i> , 2023, 6, .	2.8	0
1588	Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	9
1589	Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada. <i>JAMA Network Open</i> , 2023, 6, e232328.	2.8	15
1590	B cell-related tertiary lymphoid structure may exert inhibitory effects on lung adenocarcinoma and SARS-COV-2. <i>Heliyon</i> , 2023, 9, e14334.	1.4	0
1591	Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2. <i>CRISPR Journal</i> , 0, , .	1.4	0
1592	Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. <i>Nature Immunology</i> , 2023, 24, 690-699.	7.0	16
1593	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1594	Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients. <i>Microorganisms</i> , 2023, 11, 755.	1.6	0
1595	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
1596	Computational Protein Design for COVID-19 Research and Emerging Therapeutics. <i>ACS Central Science</i> , 2023, 9, 602-613.	5.3	4
1597	Comparison of the disease severity with infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants: A meta-analysis. , 2023, 2, .		0
1598	Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	0
1599	Genome surveillance of SARS-CoV-2 variants and their role in pathogenesis focusing on second wave of COVID-19 in India. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1600	Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. <i>Journal of Immunology</i> , 2023, 210, 1236-1246.	0.4	4
1601	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2

#	ARTICLE	IF	CITATIONS
1602	Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1603	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
1604	Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1. <i>Life Science Alliance</i> , 2023, 6, e202201745.	1.3	8
1606	Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
1607	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
1608	Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1609	A new setâ€up of vanishing antibodies: A biennial followâ€up of five different clients' humoral responses against SARSâ€CoVâ€2 after systemic vaccination in an oncology hospital in Poland. <i>Health Science Reports</i> , 2023, 6, .	0.6	0
1610	Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1611	Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals. <i>Nature Communications</i> , 2023, 14, .	5.8	10
1612	Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India. <i>Cureus</i> , 2023, , .	0.2	0
1613	Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study. <i>European Neuropsychopharmacology</i> , 2023, 71, 96-108.	0.3	4
1614	Novel Therapeutic Targets for SARS-CoV-2 and COVID-19. , 2024, , 308-325.		0
1615	Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. <i>Communications Biology</i> , 2023, 6, .	2.0	4
1616	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
1617	Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. <i>Infection, Genetics and Evolution</i> , 2023, 111, 105434.	1.0	1
1618	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	3
1619	A Review of the Mental Health Sequelae of the SARS-CoV-2 (COVID-19): Preparedness Perspective. <i>Cureus</i> , 2023, , .	0.2	0
1620	Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1

#	ARTICLE	IF	CITATIONS
1622	A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. <i>PLoS Pathogens</i> , 2023, 19, e1011298.	2.1	5
1623	Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication. <i>Microbes and Infection</i> , 2023, , 105142.	1.0	0
1625	Immune Imprinting and Implications for COVID-19. <i>Vaccines</i> , 2023, 11, 875.	2.1	10
1649	Comparative Analysis of SARS-CoV-2 Variants Across Three Waves in India. , 2023, , 104-118.		0
1663	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 3-26.	0.8	0
1688	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
1718	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
1730	Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis. <i>European Journal of Pediatrics</i> , 0, , .	1.3	0
1733	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1529-1543.		0
1743	Virulence and infectivity were associated with different fragments in the Delta subtype of SARS-CoV-2. , 0, , .		0
1746	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
1794	Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2024, , 33-61.	0.8	0